cell
By expressing CD7-targeting peptides and functionally downregulating miRNAs in donor cells, the self-destructive and immune rejection problems in CD7 CAR T-cell therapy are solved, achieving effective targeted killing of CD7+ tumor cells and improving safety, making it suitable for the treatment of CD7+ diseases.
Patent Information
- Application Number
- CN202580028938.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2024-02-27
- Filing Date
- 2025-02-27
- Publication Date
- 2026-11-17
AI Technical Summary
Existing CD7 CAR T-cell therapies suffer from cannibalism and immune system rejection when treating CD7+ diseases, and allogeneic CAR T-cell preparation carries safety risks, making it difficult to effectively target CD7+ tumor cells without damaging normal tissues.
By expressing CD7-targeting peptides and functionally downregulated miRNAs in donor cells, cannibalism and immune rejection are reduced, cell efficacy and persistence are improved. Nucleic acid constructs are used for gene editing, including CD7-targeting CARs and miRNA hairpins, to regulate immune signal transduction pathways and enhance targeting and safety.
It achieves effective targeted killing of CD7+ tumor cells, reduces the risk of cannibalism and immune rejection, and improves the therapeutic durability and safety of CAR T cells, making it suitable for the treatment of CD7+ diseases such as T-cell malignancies.
Smart Images

Figure CN123124995A_ABST
Abstract
Description
Background of the Invention
[0002] Invention Field
[0003] This invention generally relates to the fields of oncology and molecular biology. More specifically, this invention relates to allogeneic CD7 CAR T cells for targeting and treating CD7+ diseases, such as CD7-positive malignancies.
[0004] Related fields description
[0005] CD7 (differentiation cluster 7) is a transmembrane glycoprotein and a cell surface co-stimulatory molecule. CD7 appears early in T cell development and plays a crucial role in the interactions between T cells and between T cells and B cells during early lymphocyte development. CD7 is expressed on human T cells and natural killer (NK) cells, as well as on cells in the early stages of T cell, B cell, and myeloid cell differentiation. In CD8+ T cells, CD7 can be used to define different cell subsets or as a marker of CD8 T cell differentiation. This corresponds to three cell populations: CD7-high, low, and CD7-negative cells, which further form cell subsets with different functions and phenotypic characteristics. It has been reported that the β-galactosyl-binding lectin galactoglucan-1 can bind to CD7 and induce apoptosis in thymocytes and T cells, which is associated with the development of T cell malignancies and other diseases.
[0006] CD7 is expressed in more than 95% of acute T-cell leukemia (T-ALL), NK / T-cell lymphoma (TCL), acute myeloid lymphoma, and certain types of peripheral T-cell lymphoma. Therefore, CD7 is an attractive therapeutic target for T-cell malignancies, as its expression is normally limited to T cells and NK cells, thus reducing the risk of off-target organ toxicity.
[0007] T-cell malignancies are a heterogeneous group of diseases characterized by clonal proliferation and T-cell dysfunction, broadly classified into TCL and T-ALL. Initial treatment with conventional chemotherapy often results in severe toxicity, and the efficacy is insufficient to maintain remission. Despite some progress in this field, new targeted therapies are still needed to improve patient outcomes.
[0008] Chimeric antigen receptor (CAR) T-cell therapy is one of the most promising cancer immunotherapies. Due to the similarities between B-cell and T-cell lymphomas, extending CAR T-cell therapy to T-cell malignancies holds great promise.
[0009] Adoptive cell therapy (ACT), specifically using T-cells engineered with T-cell receptors (TCRs) and CAR T cells, has brought great hope for treating cancers, as well as certain infectious and autoimmune diseases. It has been reported to have extremely high cure rates for some cancers, specifically hematologic malignancies (Jackson et al., 2016); while for other malignancies, specifically solid tumors, treatment success rates are relatively limited (O'Hara, 2016; Han et al., 2017; Irving et al., 2017). Many treatment failures are attributed to an unfavorable tumor microenvironment, which forms physical, molecular, and immunosuppressive barriers that hinder the function of engineered immune cells. Similarly, to date, no constructs have been developed that can stimulate immune cell activity or inhibit immune checkpoints.
[0010] Applying CD7-based CAR T-cell therapy in practice presents challenges because healthy and malignant T cells share the same target antigen. This shared antigenicity can lead to fratricide in CAR-transduced T cells, as incomplete internalization of CD7 on the T cell surface after CAR expression hinders cell production and affects their survival. Furthermore, administration may result in the depletion of normal peripheral T cells, leading to severe immunodeficiency. Compared to the effects of therapies such as CD19-based CAR T-cells that deplete normal B cells, this effect of targeting normal tissues outside the tumor may be more severe and more difficult to treat.
[0011] Previous studies have shown that targeted genomic disruption of the CD7 gene can prevent the aforementioned cannibalism and enable the proliferation of CD7CAR T cells without impairing their cytotoxic function. Studies have also demonstrated that CD7CAR T cells exhibit potent cytotoxicity against malignant T cell lines and can provide protection in a T-ALL mouse xenograft model.
[0012] Allogeneic CAR T cells, prepared from healthy donor T cells, can provide ready-to-use, cell-free therapeutic products, but may require further modification to prevent graft-versus-host disease and rejection by recipient immune cells. Previously, allogeneic CAR T cells were prepared using gene-editing techniques that induce DNA double-strand breaks, which could lead to unintended target site editing and potentially unforeseen consequences.
[0013] CAR T-cell therapy has become a well-established treatment for B-cell malignancies and myeloma, and its use in treating other cancers is expected to receive regulatory approval as well. The field is rapidly developing as these therapies continue to improve in terms of safety, efficacy, and feasibility. Invention Overview
[0015] In a first aspect, the present invention provides an engineered donor cell that expresses a CD7-targeting polypeptide and one or more microRNAs (miRNAs) that functionally downregulate the target in the cell.
[0016] In this embodiment, the CD7-targeting polypeptide binds specifically to CD7.
[0017] In some embodiments, the CD7-targeting peptide may be an engineered T-cell receptor that targets CD7, such as a chimeric antigen receptor (CAR) that targets CD7.
[0018] In this embodiment, the miRNA can promote cell proliferation, reduce cell alloreactivity, reduce immune system rejection of cells, reduce the degree of lymphocyte clearance, reduce cell cannibalism, and / or improve cell efficacy and persistence, thereby achieving a lasting therapeutic effect.
[0019] In this embodiment, the miRNA functionally downregulates one or more of TCR, CD7, HLA-I, and HLA-II.
[0020] In a preferred embodiment of the present invention, the miRNA functionally downregulates CD7 by inhibiting CD7 expression.
[0021] In this embodiment, the miRNA functionally downregulates TCR by inhibiting the expression of TRa, TCRb, CD3d, CD3g, CD3e and / or CD3z.
[0022] In this embodiment, the miRNA functionally downregulates HLA-II by inhibiting the expression of one or more of HLA-II peptides, CIITA, RFX5, RFXANK, and / or RFXAP.
[0023] In this embodiment, the engineered donor cells also express miRNAs, which functionally downregulate the expression of one or more of the following: CD5, B2M, CD3z, CD3e, CD3d, CD3g, TCRRa, TCRb, CIITA, RFX5, RFXANK, RFXAP, TIM-3, PD-1, CD52, TIGIT, LAG-3, CTLA-4, DNMT3A, NR4A3, PRDM1, TGFBR2, REGNASE-1, ROQUIN-1, CCR5, and GM-CSF.
[0024] In one embodiment, one or more surface-expressed peptides involved in immune signal transduction are upregulated, optionally through transcripts expressing the peptide.
[0025] In this implementation, the upregulated surface-expressed peptide involved in immune signal transduction can be a non-classical HLA class I peptide, CD47, and / or PD-L1.
[0026] In this embodiment, surface-expressed non-classical HLA class I molecules are upregulated, while surface-expressed HLA class I molecules are downregulated. In this embodiment, the non-classical HLA class I peptides are genetically modified HLA-E, HLA-G, or HLA-F peptides.
[0027] In embodiments of the present invention, surface-expressed CAR is upregulated, while surface-expressed TCR is downregulated.
[0028] In an embodiment of the present invention, the engineered donor cells express a safety switch gene or a suicide gene.
[0029] In a second aspect, the present invention provides a nucleic acid construct comprising a sequence encoding a CD7-targeting polypeptide and one or more miRNA hairpins.
[0030] In an embodiment of the nucleic acid construct of the present invention, the nucleic acid construct comprises at least a first miRNA hairpin and a second miRNA hairpin, wherein the first miRNA hairpin and the second miRNA hairpin respectively target a combination of two sequences, wherein each of the two sequences is independently selected from sequences having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with any one of the sequences in SEQ ID NO: 1 to 128 or SEQ ID NO: 282 to 293.
[0031] In an embodiment, the CD7-targeting polypeptide comprises a polypeptide encoded by a polynucleotide sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with SEQ ID NO: 129, SEQ ID NO: 130, SEQ ID NO: 131, SEQ ID NO: 132, SEQ ID NO: 133, or SEQ ID NO: 134.
[0032] In another embodiment, the CD7-targeting polypeptide comprises a polypeptide sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with SEQ ID NO: 135, SEQ ID NO: 136, SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 139, or SEQ ID NO: 140.
[0033] In an embodiment of the nucleic acid construct of the present invention, the construct contains at least two different miRNA hairpins that target different regions of the same transcript.
[0034] In one embodiment, the construct comprises at least two different miRNA hairpins that target different transcripts of the same gene.
[0035] In one embodiment, the construct comprises at least two different miRNA hairpins that target different splice variants of the same gene.
[0036] In one embodiment, there are two copies of the first miRNA hairpin and / or two copies of the second miRNA hairpin. In another embodiment, there are three copies of the first miRNA hairpin and / or two copies of the second miRNA hairpin.
[0037] In an embodiment of the nucleic acid construct of the present invention, the construct includes a promoter element configured to express one or more miRNA hairpins, wherein the promoter element is optionally a promoter.
[0038] In an implementation, the promoter is a eukaryotic promoter, optionally wherein the eukaryotic promoter is a Pol II promoter or a Pol III promoter.
[0039] In this embodiment, the promoter is an inducible promoter, a tissue-specific promoter, a cell lineage-specific promoter, or a synthetic promoter.
[0040] In this embodiment, the promoter is a UBI promoter. In this embodiment, the promoter is an EF1α promoter, a derivative of the EF1α promoter, or a short EF1 promoter; preferably, the promoter is a short EF1 promoter.
[0041] In embodiments of the nucleic acid construct of the present invention, the nucleic acid construct further includes a promoter element configured to express a CD7-targeting peptide, optionally wherein the promoter element is a promoter. In embodiments, the promoter configured to express the CD7-targeting peptide is a PGK promoter, an EF1α promoter, a derivative of an EF1α promoter, or a short EF1 promoter.
[0042] In an embodiment of the nucleic acid construct of the present invention, the nucleic acid construct further includes a spacer, wherein the spacer optionally includes an enhancer; further optionally, the spacer is an enhancer.
[0043] In an embodiment, the spacer is at least 50 nucleotides in length.
[0044] In one embodiment, the spacer is 50 to 1,000 nucleotides in length. In another embodiment, the spacer is 50 to 900, 50 to 800, 100 to 800, or 50 to 800 nucleotides in length.
[0045] In an embodiment, the length of the spacer is at least 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180 or 200 nucleotides.
[0046] In an embodiment, the spacer is a GFP sequence, and the GFP sequence has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with SEQ ID NO: 141.
[0047] In one embodiment, the spacer is located between the promoter configured to express the miRNA hairpin and the miRNA hairpin.
[0048] In one embodiment, the spacer is heterogeneous relative to the promoter element. In another embodiment, the spacer comprises an encoded open reading frame.
[0049] In an embodiment of the nucleic acid construct of the present invention, the CD7-targeting polypeptide specifically binds to CD7, wherein optionally the CD7-targeting polypeptide is an engineered T-cell receptor that targets CD7, and optionally the CD7-targeting polypeptide is a CAR that targets CD7. In an embodiment, the sequence encoding the CD7-targeting polypeptide comprises a polynucleotide sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with SEQ ID NO: 129, SEQ ID NO: 130, SEQ ID NO: 131, SEQ ID NO: 132, SEQ ID NO: 133, or SEQ ID NO: 134; and / or wherein the CD7-targeting polypeptide comprises a polypeptide sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with SEQ ID NO: 135, SEQ ID NO: 136, SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 139, or SEQ ID NO: 140.
[0050] In an embodiment of the nucleic acid construct of the present invention, the miRNA hairpin is controlled by a first promoter, while the sequence encoding the CD7 targeting polypeptide is controlled by a second promoter.
[0051] In another embodiment, the miRNA hairpin and the sequence encoding the CD7-targeting polypeptide are controlled by a single promoter.
[0052] In an embodiment of the nucleic acid construct of the present invention, the construct further includes a screening gene.
[0053] In this embodiment, the screening gene is LNGFR, truncated endothelial growth factor receptor (tEGFR), tCD19, CD20 or truncated CD20 (tCD20), tCD34 or its derivatives.
[0054] In embodiments of the nucleic acid construct of the present invention, the construct further comprises a sequence encoding a suicide gene or a safety switch gene.
[0055] In an embodiment, the suicide gene or safety switch gene is selected from the group consisting of: herpes simplex virus thymidine kinase (HSV-tk), inducible caspase 9 (iCasp9), truncated endothelial growth factor receptor (tEGFR), RQR8, dihydrofolate reductase (DHFR), CD20 or truncated CD20 (tCD20), thymidine synthase (TYMS), and lenalidomide OFF-switch CAR molecules.
[0056] In embodiments of the nucleic acid construct of the present invention, the construct further includes an internal ribosome entry site (IRES).
[0057] In a third aspect, the present invention provides a DNA molecule, plasmid, or vector comprising the nucleic acid construct described herein, wherein optionally the vector is an expression vector, and optionally the expression vector is an adenovirus, adeno-associated virus, retrovirus, or lentiviral vector.
[0058] In a fourth aspect, the present invention provides a method for preparing engineered donor cells, comprising transfecting or transducing cells using the nucleic acid constructs, DNA molecules, plasmids or vectors described in the present invention.
[0059] In one embodiment, the present invention provides a method for preparing engineered donor cells from a patient donor or a healthy donor, comprising: (a) collecting cells from the donor; and (b) transfecting or transducing the cells using the nucleic acid construct, DNA molecule, plasmid, or vector described in the present invention; and (c) expressing the nucleic acid construct. In another embodiment, the engineered donor cells are T cells.
[0060] It should be understood that, in some embodiments, the present invention covers the in vivo delivery of the nucleic acid constructs, DNA molecules, plasmids or vectors described herein to cells.
[0061] In this embodiment, the nucleic acid construct, DNA molecule, plasmid, or vector downregulates the TCR peptide and upregulates the CAR peptide targeting CD7. The engineered donor cells can be CAR T cells.
[0062] In a fifth aspect, the present invention provides an engineered donor cell that can be obtained or acquired by the method of the present invention.
[0063] In a sixth aspect, the present invention provides a cell comprising the nucleic acid construct, DNA molecule, plasmid or vector described in the present invention, optionally wherein the cell is an engineered donor cell.
[0064] In the embodiments of the engineered donor cells of the present invention, the engineered donor cells are eukaryotic cells, such as mammalian cells.
[0065] In this embodiment, the engineered donor cells are immune effector cells.
[0066] In this embodiment, the immune effector cells are selected from the group consisting of: αβ T cells, γδ T cells, tumor-infiltrating lymphocytes (TILS), TCR-engineered T cells, CAR T cells, NK cells, NK / T cells, regulatory T cells, mucosa-associated inert T cells (MAIT), monocytes, and macrophages. In this embodiment, the immune effector cells are CAR T cells.
[0067] In the embodiments of the engineered donor cells of the present invention, the engineered donor cells are stem cells or progenitor cells.
[0068] In one embodiment, the engineered donor cells are pluripotent stem cells, such as embryonic stem cells and / or induced pluripotent stem cells. In an alternative embodiment, the engineered donor cells are multipotent stem cells, such as hematopoietic stem cells.
[0069] In the embodiment of the engineered donor cells of the present invention, the engineered donor cells are differentiated cells.
[0070] In a seventh aspect, the present invention provides a composition comprising the engineered donor cells described herein, and optionally further comprising a pharmaceutically acceptable carrier, excipient, diluent, or salt.
[0071] In an eighth aspect, the present invention provides a method for eliminating CD7+ cells in vitro, ex vivo, or in vivo, comprising contacting the CD7+ cells with the engineered donor cells or composition described in the present invention.
[0072] In a ninth aspect, the present invention provides the use of the engineered donor cells, nucleic acid constructs, DNA molecules, plasmids, vectors or compositions described herein in a method of treating a disease.
[0073] In one embodiment, the method of treating the disease includes administering to a subject in need the engineered donor cells, nucleic acid constructs, DNA molecules, plasmids, vectors, or compositions described herein.
[0074] In embodiments, the engineered donor cells, nucleic acid constructs, DNA molecules, plasmids, vectors, or compositions described in this invention are used to manufacture drugs for treating diseases.
[0075] In one implementation, the disease may be selected from cancer, infectious diseases, autoimmune diseases, or hereditary conditions. In one implementation, the cancer is a T-cell malignancy, such as leukemia or lymphoma.
[0076] In an alternative implementation, the disease is a disease associated with CD7+ cells.
[0077] In an eleventh aspect, the present invention provides a miRNA hairpin, wherein the miRNA hairpin targets a sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with any of the sequences in SEQ ID NO: 1 to 128 or SEQ ID NO: 282 to 293.
[0078] In a twelfth aspect, the present invention provides a miRNA hairpin, wherein the miRNA hairpin comprises a sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with any of the sequences in SEQ ID NO: 142 to 281.
[0079] In a thirteenth aspect, the present invention provides a VHH antibody or antibody fragment, wherein the VHH antibody or antibody fragment targets a polypeptide sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with any one of the sequences in SEQ ID NO: 135, SEQ ID NO: 136, SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 139, or SEQ ID NO: 140.
[0080] Brief description of the attached figures
[0081] Figure 1A and Figure 1B This is a nucleic acid construct containing gene silencing boxes and gene expression boxes. The figure shows six miRNA hairpins for silencing target genes, the CD7 VHH as the anti-CD7 CAR portion, and the RQR8 reporter gene / safety switch, separated by a 2A peptide.
[0082] Figure 2 The downregulation of CD7 expression in genetically modified primary T cells is represented by flow cytometry histograms, which also show the percentage of cells expressing CD7 and the normalized MFI value. These histograms were obtained based on gate selection analysis of genetically modified mCherry-positive T cells.
[0083] Figure 3 The expansion of genetically modified T cells after transduction with a bimodal construct carrying a control anti-CD7 CAR (CAR7), and with and without CD7 silencing using miRNA CD7_T12. Introducing CD7 silencing resulted in superior cell proliferation, indicating a functional relevance of CD7 silencing.
[0084] Figure 4A: Schematic diagram of the CAR T cell preparation process.
[0085] Figure 4B : Expansion of miCAR7 T cells during preparation. All miCAR constructs achieved silencing of TCR, HLA-I, and CD7, and the VHH bindings on the CAR were interchanged: 1185(F11), 1186(B10), 1187(F04), 1188(C11), 1189(D01), 1190(G02). UTD, untransduced T cells.
[0086] Figure 4C Immunophenotypic characterization of miCAR7 T cells after removal of TCR α / β positive cells is presented as a flow cytometry scatter plot. All miCAR constructs achieved silencing of TCR, HLA-I, and CD7, and interchanged VHH conjugates on the CAR: 1185 (F11), 1186 (B10), 1187 (F04), 1188 (C11), 1189 (D01), and 1190 (G02). UTD, untransduced T cells. CAR-positive cells were detected based on RQR8 co-expression (CD34). After removal of TCR α / β positive cells, the remaining cells did not express TCR α / β, HLA-ABC and CD7 expression were silenced, and the RQR8 reporter gene (CD34) was fully expressed.
[0087] Figure 4D Immunophenotypic characterization of miCAR7 T cells after removal of TCR α / β-positive cells, expressed as cell percentage and mean fluorescence intensity (MFI). All miCAR constructs achieved silencing of TCR, HLA-I, and CD7, and interchanged VHH conjugates on the CAR: 1185 (F11), 1186 (B10), 1187 (F04), 1188 (C11), 1189 (D01), and 1190 (G02). UTD, untransduced T cells. Anti-CD7 CARs were detected using recombinant CD7 protein (RecCD7), and RQR8 co-expression was detected using anti-CD34 antibody.
[0088] Figure 5Specific cytotoxic effects of miCAR7 T cells on tumor cells. In short-term cytotoxicity assays, miCAR7 T cells carrying different anti-CD7 VHH cells exhibited varying functional activities against CD7-expressing tumor cells. Only VHH B10, C11, D01, and G02 cells effectively eliminated CD7-positive tumor cells. Engineered miCAR7 T cells (effective cells, E) were co-cultured with SUP-T1 cells (target cells, T) at E:T ratios of 1:1, 1:3, and 1:9 for 24, 48, 72, and 96 hours, respectively. At the indicated time points, CTV positivity was assessed by flow cytometry to evaluate target cell viability, with SUP-T1 cells labeled with CTV. In long-term recursive killing experiments, only miCAR7 T cells carrying anti-CD7 VHH B10, C11, D01, and G02 were able to effectively eliminate tumor cells after four rounds (for MOLT-4) or two to three rounds (for SUP-T1) of restimulation / repetitive stimulation with equal amounts of target cells.
[0089] Figure 6 Tolerance assessment of B10 VHH miCAR7 T cells in NSG mice. Mice were administered miCAR7 T cells expressing the B10 VHH conjugate, which has previously been shown to have potent targeting activity in vitro. These miCAR7 T cells also silenced TCRα / β, HLA-I, and CD7, allowing for the removal of residual TCRα / β-expressing T cells through purification. On day 1 of the study, mice (n=3) were given a single dose of 7.5 × 10⁶ cells via tail vein injection. 6 Each mouse was charged with 7.5 × 10⁵ cells, followed by daily body weight measurements for two consecutive weeks. The figure shows the relative body weight curves during the 15-day observation period, expressed as a percentage of initial body weight. Daily body weight measurements were taken to assess tolerance and overall health of the mice. Data are presented as individual values for each mouse. No significant weight loss or adverse reactions were observed during the study, indicating that NSG mice exhibited good tolerance to miCAR7 T cells during the 15-day observation period. This result suggests that administration of 7.5 × 10⁵ cells to the mice is effective. 6 One dose of CAR T cells did not cause severe toxicity or cachexia-like symptoms in the treated animals.
[0090] Figure 7A In an ALL xenograft mouse model, the anti-leukemic activity of B10 VHH miCAR7 T cells targeting three genes was demonstrated. Mice were administered miCAR7 T cells expressing B10 VHH conjugates, while TCRα / β, HLA-I, and CD7 were simultaneously silenced. The figure shows a schematic diagram of the experimental design for the CCRF-CEM xenograft model. Luciferase-labeled CCRF-CEM cells (3 × 10⁻⁶) were implanted.5 Five days after administration, mice were injected with miCAR7 T cells (0.2 × 10⁻⁶). 6 1.5×10 6 Or 6.5×10 6 (6.4 × 10) or miCAR19 T cells (6.4 × 10) 6 BLI was performed on day 4, before T cell injection, and then twice a week thereafter (n=6 mice per treatment group).
[0091] Figure 7B On the dates indicated, mice implanted with CCRF-CEM cells and treated with only a carrier (PBS), miCAR7 T cells, or miCAR19 T cells were subjected to bioluminescence imaging (BLI).
[0092] Figure 7C Quantitative analysis of BLI signals in mice in each treatment group showed that miCAR7 T cells have dose-dependent antitumor activity, with the highest dose effectively controlling tumor growth, while the two lower doses had weaker efficacy.
[0093] Figure 8A Immunophenotyping of multi-engineered miCAR7 T cells with silencing capabilities for four target genes. After purification by removing TCRα / β-positive cells, the expression of anti-CD7 CAR and the RQR8 safety switch on T cells was detected. CAR molecules were detected using fluorescently labeled recombinant CD7 protein, and co-expression of RQR8 was detected using anti-CD34 antibody.
[0094] Figure 8B Residual expression of silenced targets was assessed based on mean relative fluorescence intensity (MFI) compared to untransduced T cells. As expected, residual expression of TCRα / β was negligible after removal of TCRα / β-positive cells; similarly, expression of HLA-II (HLA-DP, DQ, DR) and CD7 was also negligible. The silencing level of HLA-I (HLA-ABC) was modulated to 75%–85% using an optimized gene construct carrying a miRNA targeting B2M_T2. All miCAR constructs were designed to silence TCRα / β, HLA-I, HLA-II, and CD7, with interchangeable VHH bindings on the CARs: 1293 (B10), 1549 (C11), 1567 (D01), and 1570 (G02).
[0095] Figure 9ASpecific cytotoxic effects of miCAR7 T cells with four target gene silencing capabilities on tumor cells. (A) In short-term cytotoxicity assays, miCAR7 T cells carrying different anti-CD7 VHHs exhibited considerable functional activity against CD7-expressing tumor cells. Engineered miCAR7 T cells (effective cells, E) and tumor cells (target cells, T) were co-cultured at an E:T ratio of 1:1 for 24, 48, and 72 hours. At the indicated time points, the survival of target cells (MOLT-4 or SUP-T1 cells expressing GFP) was assessed by flow cytometry. Anti-CD19 CAR T cells with silenced TCRα / β and HLA-I were used as controls.
[0096] Figure 9B In long-term repeated killing assays, miCAR7 T cells were also able to effectively eliminate MOLT-4 or SUP-T1 tumor cells. For MOLT-4 cells, the elimination effect lasted from one round (1549) to six rounds (1293, 1567, and 1570); for SUP-T1 cells, it lasted for two rounds of restimulation with the same number of target cells. All miCAR constructs were designed to silence TCRα / β, HLA-I, HLA-II, and CD7, and the VHH bindings on the CAR were interchanged: 1293 (B10), 1549 (C11), 1567 (D01), and 1570 (G02). Anti-CD19 CAR T cells with silenced TCRα / β and HLA-I were used as controls. Detailed Implementation
[0097] This invention generally relates to engineered donor cells, nucleic acid constructs, miRNA hairpins, VHH antibody conjugates, methods for preparing engineered donor cells, and methods for treatment using said engineered donor cells, nucleic acid constructs, or other products of this invention.
[0098] This invention relates to engineered donor cells expressing a CD7-targeting peptide and one or more microRNAs (miRNAs).
[0099] The one or more miRNAs functionally downregulate the target in the cell.
[0100] CD7-targeting peptide
[0101] The engineered donor cells and nucleic acid constructs of this invention express CD7-targeting peptides.
[0102] The CD7-targeting peptide can be an engineered T-cell receptor that targets CD7, such as a chimeric antigen receptor (CAR) that targets CD7.
[0103] In a preferred embodiment, the CD7-targeting polypeptide comprises a polypeptide encoded by a polynucleotide sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with SEQ ID NO: 129, SEQ ID NO: 130, SEQ ID NO: 131, SEQ ID NO: 132, SEQ ID NO: 133, or SEQ ID NO: 134.
[0104] In a preferred embodiment, the CD7-targeting polypeptide comprises a polypeptide encoded by a polynucleotide sequence, the polynucleotide sequence comprising or consisting of SEQ ID NO: 129, SEQ ID NO: 130, SEQ ID NO: 131, SEQ ID NO: 132, SEQ ID NO: 133 or SEQ ID NO: 134.
[0105] In another embodiment, the CD7-targeting polypeptide comprises a polypeptide sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with SEQ ID NO: 135, SEQ ID NO: 136, SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 139, or SEQ ID NO: 140.
[0106] In a preferred embodiment, the CD7-targeting polypeptide comprises a polypeptide encoded by a polynucleotide sequence, the polynucleotide sequence comprising or consisting of SEQ ID NO: 135, SEQ ID NO: 136, SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 139 or SEQ ID NO: 140.
[0107] Table 1 - CD7 Target Nucleotide Sequences
[0108] Table 2 - CD7 Targeting Peptide Sequences
[0109] microRNAs (miRNAs)
[0110] This invention includes one or more miRNAs.
[0111] miRNA is a type of inhibitory nucleic acid.
[0112] Inhibitory nucleic acids are well known in the art. For example, siRNA, shRNA, and double-stranded RNA are described in U.S. Patents 6,506,559 and 6,573,099, and U.S. Patent Publications 2003 / 0051263, 2003 / 0055020, 2004 / 0265839, 2002 / 0168707, 2003 / 0159161, and 2004 / 0064842, the entire contents of which are incorporated herein by reference.
[0113] Since Fire and colleagues discovered RNA interference (RNAi) in 1998, its biochemical mechanisms have been rapidly elucidated. Double-stranded RNA (dsRNA) is cleaved by Dicer, a ribonuclease belonging to the RNase III family. This process produces miRNAs approximately 21 nucleotides in length. These miRNAs are integrated into a multiprotein RNA-induced silencing complex (RISC), which targets the target mRNA under the guidance of the miRNA. The RISC cleaves the target mRNA in the middle of its complementary region. In mammalian cells, related miRNAs have also been found, which are shorter RNA fragments (approximately 22 nucleotides). These miRNAs are produced from longer precursors (approximately 70 nucleotides) cleaved by Dicer-mediated cleavage, and these precursors have imperfectly paired hairpin RNA structures. The miRNAs are integrated into miRNA-protein complexes (miRNPs), thereby inhibiting the translation of the target mRNA.
[0114] When designing RNAi molecules, several factors can be considered, such as the nature of the siRNA, the duration of the silencing effect, and the choice of delivery system. Furthermore, the RNAi process is homology-dependent; therefore, sequences are typically carefully selected to maximize gene specificity while minimizing the possibility of cross-interference between homologous but gene-specific sequences. Specifically, the sequence identity between the miRNA sequence and a portion of the target gene's nucleotide sequence is typically greater than 80%, 85%, 90%, 95%, 98%, or even 100%. Sequences with sequence identity below approximately 80% may exhibit significantly reduced efficacy. Therefore, the higher the sequence identity between the miRNA and the target gene to be suppressed, the lower the likelihood of influencing the expression of irrelevant genes.
[0115] Furthermore, the length of the miRNA is also an important consideration. In some embodiments of the present invention, the length of the miRNA can be at least about 19–25 nucleotides. In the context of the present invention, the length of the miRNA can be particularly less than 500, 200, 100, 50, 25, 24, 23, or 22 nucleotides. In some embodiments, the length of the miRNA is about 15 to about 25 nucleotides, or about 19 to about 25 nucleotides. In some embodiments, the length of the miRNA can be 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, 15, 14, 12, 11, or 10 nucleotides. In some embodiments, the length of the miRNA can be 19 nucleotides. In some embodiments, the length of the miRNA can be 20 nucleotides. In some embodiments, the length of the miRNA can be 21 nucleotides. In some embodiments, the length of the miRNA can be 22 nucleotides.
[0116] To improve the effectiveness of miRNA-mediated gene silencing, guidelines have been developed for selecting mRNA target sites to optimize miRNA design (Soutschek et al., 2004; Wadhwa et al., 2004). These strategies can provide rational methods for selecting siRNA sequences to achieve maximum gene knockdown. To facilitate miRNA entry into cells and tissues, various vectors, including plasmids and viral vectors such as adenoviruses, lentiviruses, and retroviruses, have been used (Wadhwa et al., 2004).
[0117] Typically, inhibitory nucleic acids form a double-stranded structure; this double-stranded structure can be formed by two independent nucleic acids that are partially or completely complementary.
[0118] In some embodiments of the invention, the miRNA may comprise only a single nucleic acid (polynucleotide) or a nucleic acid analog and form a double-stranded structure by complementing itself, for example, forming a hairpin loop. The double-stranded structure of the miRNA may comprise 16–500 or more consecutive nucleotides, encompassing all ranges therein. The miRNA may comprise 17–35 consecutive nucleotides, more specifically 18–30 consecutive nucleotides, more specifically 19–25 nucleotides, more specifically 20–23 consecutive nucleotides, or 20–22 consecutive nucleotides, or 21 consecutive nucleotides, which hybridize with a complementary nucleic acid to form a double-stranded structure, wherein the complementary nucleic acid may be another part of the same nucleic acid or a separate complementary nucleic acid. Therefore, the miRNA may also be described as an shRNA intercalating with a miRNA.
[0119] miRNAs can be obtained from commercial or natural sources and can be synthesized using any of a variety of techniques well known to those skilled in the art. For example, commercial sources of pre-designed miRNAs include Invitrogen's Stealth™ Select technology (Carlsbad, California, USA), Ambion® (Austin, Texas, USA), and Qiagen® (Valencia, California, USA).
[0120] In the most preferred embodiment, the miRNAs included in this invention are constructed according to the miRNA structure and design described in WO2019186274, the entire contents of which are incorporated herein by reference.
[0121] The nucleic acid construct of the present invention comprises a miRNA that functionally downregulates a target in cells.
[0122] The miRNAs described in this article are preferably derived from miRNA hairpins.
[0123] In one embodiment, the miRNA can improve cell proliferation, reduce cell alloreactivity, reduce immune system rejection of cells, reduce lymphocyte clearance of cells, reduce cell cannibalism, and / or improve cell efficacy and persistence, thereby achieving a lasting therapeutic effect.
[0124] In one embodiment, the miRNA is functionally downregulated by inhibiting the expression of one or more of TCR, CD7, HLA-I, and HLA-II.
[0125] In a preferred embodiment of the present invention, the miRNA functionally downregulates CD7 by inhibiting its expression.
[0126] In an implementation, the miRNA functionally downregulates the TCR, such as by inhibiting the expression of TCRα, TCRβ, CD3d, CD3g, CD3e and / or CD3z.
[0127] In an embodiment, the miRNA functionally downregulates HLA-II, such as by inhibiting the expression of one or more of HLA-II peptides, CIITA, RFX5, RFXANK, and / or RFXAP.
[0128] In one embodiment, the nucleic acid construct comprises a miRNA that functionally downregulates TCR and a miRNA that functionally downregulates CD7.
[0129] In one embodiment, the nucleic acid construct comprises a miRNA that functionally downregulates TCR and a miRNA that functionally downregulates HLA-I.
[0130] In one embodiment, the nucleic acid construct comprises a miRNA that functionally downregulates TCR and a miRNA that functionally downregulates HLA-II.
[0131] In one embodiment, the nucleic acid construct comprises a miRNA that functionally downregulates CD7 and a miRNA that functionally downregulates HLA-I.
[0132] In one embodiment, the nucleic acid construct comprises a miRNA that functionally downregulates CD7 and a miRNA that functionally downregulates HLA-II.
[0133] In one embodiment, the nucleic acid construct of the present invention comprises miRNAs that functionally downregulate HLA-I and miRNAs that functionally downregulate HLA-II.
[0134] In one embodiment, the nucleic acid construct of the present invention comprises miRNAs that functionally downregulate two, three, four, five, six, seven, eight, nine, ten or more targets.
[0135] In one embodiment, the nucleic acid construct of the present invention comprises one, two, three, four, five, six, seven, eight, nine, or ten miRNAs.
[0136] In one embodiment, the nucleic acid construct may contain two copies of a first miRNA hairpin and two copies of a second miRNA hairpin.
[0137] In another embodiment, the nucleic acid construct may contain three copies of a first miRNA hairpin and three copies of a second miRNA hairpin.
[0138] In another embodiment, the nucleic acid construct may contain at least two different miRNA hairpins that target different regions of the same transcript.
[0139] In another embodiment, the nucleic acid construct may contain at least two different miRNA hairpins that target different transcripts of the same gene.
[0140] In another embodiment, the nucleic acid construct may contain at least two different miRNA hairpins that target different splice variants of the same gene.
[0141] In this embodiment, the engineered donor cells also express miRNAs, which are functionally downregulated by inhibiting the expression of one or more of the following: CD5, B2M, CD3z, CD3e, CD3d, CD3g, TCRα, TCRβ, CIITA, RFX5, RFXANK, RFXAP, TIM-3, PD-1, CD52, TIGIT, LAG-3, CTLA-4, DNMT3A, NR4A3, PRDM1, TGFBR2, REGNASE-1, ROQUIN-1, CCR5, and GM-CSF.
[0142] In one implementation, the miRNA may target one or more sequences listed in Table 3 below.
[0143] Table 3: Target sequences of miRNAs
[0144] In Table 3 above, the first column represents the target protein (for ease of identification, some other names for the targets are also listed); the second column represents the identifier of the target sequence; and the fourth column represents the sequence targeted by the miRNA. Therefore, for example, for any miRNA of the present invention that includes a miRNA hairpin targeting CD7, it is understood that the miRNA hairpin targeting CD7 is preferably capable of targeting any one of CD7_1 to CD7_12, these target sequences being defined by the sequences provided in the fourth column. This description applies to each gene and its associated target sequence listed in Table 3.
[0145] In embodiments, the miRNA targets contained in the engineered donor cells or nucleic acid constructs of the present invention have 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with the sequences listed in Table 3.
[0146] In the embodiments, the miRNA contained in the engineered donor cells or nucleic acid constructs of the present invention has one, two, three, four or five mismatched sequences with the sequences listed in Table 3.
[0147] In a preferred embodiment, the miRNA targets a polynucleotide sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with any of the sequences in SEQ ID NO: 1–128 or SEQ ID NO: 282–293.
[0148] In a preferred embodiment, the miRNA target comprises or consists of a polynucleotide sequence comprising any one of the sequences in SEQ ID NO: 1–128 or SEQ ID NO: 282–293.
[0149] In an embodiment, the miRNA targets one, two, three, four, or five mismatched sequences with any of the sequences in SEQ ID NO: 1–128 or SEQ ID NO: 282–293.
[0150] Table 4: miRNA hairpin sequences
[0151] In Table 4 above, the first column represents the target protein (some other names for the target are also listed for ease of identification); the second column represents the identifier of the miRNA hairpin sequence; and the fourth column represents the sequence of the miRNA hairpin. Therefore, for example, for any miRNA in this invention that contains a miRNA hairpin targeting CD7, it is understood that the miRNA hairpin targeting CD7 can be any one of CD7_1 to CD7_12, as defined by the sequence provided in the fourth column. The above description applies to each gene and its associated miRNA hairpin sequence listed in Table 4.
[0152] In the embodiments, the miRNA hairpins contained in the engineered donor cells or nucleic acid constructs of the present invention have 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with the miRNA hairpin sequences listed in Table 4.
[0153] In embodiments, the miRNA hairpins contained in the engineered donor cells or nucleic acid constructs of the present invention may have one, two, three, four, or five mutations relative to the sequences listed in Table 4.
[0154] In embodiments, the present invention also envisions using truncated forms of the miRNA hairpin sequences. Such truncated forms may have 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 20, 30, 35, 40, 45, 50 or more nucleotides deleted from one or both ends of the sequences described in Table 4.
[0155] In a preferred embodiment, the miRNA hairpin contained in the engineered donor cell or nucleic acid construct of the present invention has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with any one of SEQ ID NO: 142-281.
[0156] In a preferred embodiment, the miRNA hairpin sequence comprises or consists of any one of SEQ ID NO: 142-281.
[0157] In embodiments, the miRNA hairpins contained in the engineered donor cells or nucleic acid constructs of the present invention comprise or consist of any one of SEQ ID NO: 142-281.
[0158] The miRNAs and miRNA hairpins mentioned above are also within the scope of this invention. Therefore, this invention includes miRNAs and miRNA hairpins that are independent of engineered donor cells or nucleic acid constructs.
[0159] For example, the present invention includes a miRNA, wherein the miRNA hairpin target has 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with the sequences listed in Table 3.
[0160] In the implementation, the miRNA-targeted sequence has one, two, three, four, or five mismatches relative to the sequences listed in Table 3.
[0161] In a preferred embodiment, the miRNA targets a polynucleotide sequence that has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with any one of SEQ ID NO: 1-128 or 282-293.
[0162] In a preferred embodiment, the miRNA target comprises or consists of a polynucleotide sequence consisting of any one of SEQ ID NO: 1-128 or 282-293.
[0163] In an implementation, the miRNA-targeted sequence has one, two, three, four, or five mismatches relative to any one of SEQ ID NO: 1-128 or 282-293.
[0164] In the implementation, the miRNA hairpin has 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with the miRNA hairpin sequences listed in Table 4.
[0165] In an implementation, the miRNA hairpin may have one, two, three, four, or five mutations relative to the sequences listed in Table 4.
[0166] In embodiments, the present invention also envisions using truncated forms of the miRNA hairpin sequences. Such truncated forms may have 1, 2, 3, 4, 5, 6, 7, 8, 9, 0, 11, 12, 13, 14, 15, 20, 20, 30, 35, 40, 45, 50 or more nucleotides deleted from one or both ends of the sequences described in Table 4.
[0167] In a preferred embodiment, the miRNA hairpin has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with any one of SEQ ID NO: 142-281.
[0168] In a preferred embodiment, the miRNA hairpin sequence comprises or consists of any one of SEQ ID NO: 142-281.
[0169] In an embodiment, the miRNA hairpin comprises or consists of any one of SEQ ID NO: 142-281.
[0170] Upregulation of surface-expressed peptides
[0171] In some embodiments of the present invention, one or more surface-expressed peptides of engineered donor cells may be upregulated.
[0172] In some implementations, the one or more surface-expressed peptides can be upregulated by the transcript of the peptide.
[0173] In some embodiments, the one or more surface-expressed polypeptides may participate in immune signal transduction.
[0174] In some embodiments, the upregulated surface-expressed peptide involved in immune signal transduction is a non-classical HLA-A peptide, CD47, and / or PD-L1.
[0175] In some implementations, surface-expressed non-classical HLA class I molecules are upregulated, while surface-expressed HLA class I molecules are downregulated.
[0176] In some implementations, surface-expressed HLA class I molecules can be downregulated via miRNA.
[0177] In some embodiments, the non-classical HLA class I peptide is a genetically modified HLA-E, HLA-G, or HLA-F peptide.
[0178] In some implementations, surface-expressed CAR is upregulated and surface-expressed TCR is downregulated.
[0179] In some implementations, surface-expressed CARs can be downregulated via miRNA.
[0180] Engineered donor cells
[0181] The donor cells used in the engineering modification can be derived from any cell type.
[0182] In some embodiments, the engineered donor cells are eukaryotic cells, such as mammalian cells.
[0183] In some embodiments, the engineered donor cells are immune effector cells.
[0184] In some embodiments, the immune effector cells are selected from the group consisting of αβ T cells, γδ T cells, tumor-infiltrating lymphocytes (TILs), TCR-engineered T cells, CAR T cells, NK cells, NK / T cells, regulatory T cells, mucosa-associated inert T cells (MAIT), monocytes, and macrophages.
[0185] In some embodiments, the engineered donor cells are T cells.
[0186] In some embodiments, the immune effector cells are CAR T cells.
[0187] In some embodiments, the engineered donor cells are stem cells or progenitor cells.
[0188] In some embodiments, the engineered donor cells are pluripotent stem cells, such as embryonic stem cells and / or induced pluripotent stem cells.
[0189] In some embodiments, the engineered donor cells are pluripotent stem cells, such as hematopoietic stem cells.
[0190] In some implementations, the engineered donor cells may be derived from an object, such as a human object.
[0191] In some implementations, the human object may be a healthy human object.
[0192] In some implementations, the human subject may suffer from a disease. In this case, the "subject" may be referred to as a "patient".
[0193] Antibody
[0194] This invention covers an antibody that targets a polypeptide sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with any CD7-targeting polypeptide disclosed herein.
[0195] In one embodiment, the antibody targets a polypeptide sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with any one of SEQ ID NO: 135-140.
[0196] In one embodiment, the antibody targets a polypeptide sequence comprising or consisting of any one of SEQ ID NO: 135-140.
[0197] In one embodiment, the antibody is a VHH or a VHH fragment.
[0198] Nucleic acid constructs
[0199] In this invention, expression vectors can be used to express the nucleic acid constructs of this invention. For expression to occur, the vector needs to provide appropriate signals, including various regulatory elements from viruses and mammals, such as enhancers / promoters, to drive the expression of the gene of interest in the host cell. Elements designed to optimize RNA stability in the host cell can also be defined. Furthermore, conditions for establishing permanent, stable cell clones expressing relevant products using multiple dominant drug screening markers are provided, as well as elements linking the expression of drug screening markers to peptide expression.
[0200] Control element
[0201] Throughout this application, the terms "expression construct" or "expression vector" are intended to include any type of genetic construct containing nucleic acid encoding a gene product, wherein all or part of the nucleic acid coding sequence can be transcribed. The transcript may be translated into a protein, but is not required to do so. In some embodiments, expression includes both gene transcription and translation of mRNA into a gene product. In other embodiments, expression includes only the transcription of nucleic acid encoding a target gene, i.e., the RNA molecule described herein falls into this category.
[0202] In some embodiments, the nucleic acid encoding the gene product is transcribedly regulated by a promoter element, which may be a promoter. A "promoter" is a DNA sequence recognized by the cell's transcriptional mechanisms or an introduced synthetic transcriptional mechanism that is essential for initiating the transcription of a specific gene. The phrase "transcribedly regulated" means that the promoter is in the correct position and orientation relative to the nucleic acid, thereby controlling the initiation of RNA polymerase and gene expression.
[0203] This article uses the term "promoter" to refer to a group of transcriptional control modules clustered around the transcription start sites of eukaryotic RNA polymerases (Pol) I, II, or III. Much of our understanding of promoter organization comes from analyses of several viral Pol II promoters, including the HSV thymidine kinase (tk) promoter and the SV40 early transcription unit promoter. These studies, and recent related research, indicate that promoters consist of independent functional modules, each approximately 7–20 bp in length, containing one or more recognition sites for transcriptional activators or repressors.
[0204] Each promoter contains at least one module responsible for determining the initiation site of RNA synthesis. The most well-known example is the TATA box, but in some promoters lacking the TATA box, such as the promoters of mammalian terminal deoxynucleotidyl transferase genes and SV40 late genes, independent elements covering the initiation site itself also help determine the transcription initiation location.
[0205] Other promoter elements regulate the frequency of transcription initiation. Typically, these elements are located in a region 30-110 bp upstream of the start site; however, recent studies have found that some promoters also contain functional elements downstream of the start site. The spacing between promoter elements is usually flexible, so promoter function can be preserved even if these elements are inverted or their relative positions changed. In the tk promoter, the spacing between promoter elements can increase to 50 bp before promoter activity begins to decline. Depending on the promoter, the elements appear to work synergistically or independently to activate transcription.
[0206] In some embodiments, the promoter comprises an extension factor 1 short (EF1s) promoter. In other embodiments, the human cytomegalovirus (CMV) immediate early gene promoter, the SV40 early promoter, the Rous sarcoma virus long terminal repeat sequence, the rat insulin promoter, and the glyceraldehyde-3-phosphate dehydrogenase-associated promoter can be used to achieve high-level expression of the target coding sequence.
[0207] In some embodiments of the present invention, the nucleic acid construct includes a promoter element configured to express a miRNA hairpin. The promoter element may be a promoter.
[0208] In some implementations, the promoter set to express the miRNA hairpin can be a eukaryotic promoter, such as the PolII or Pol III promoter.
[0209] In some implementations, the promoter configured to express miRNA hairpins can be an inducible promoter, a tissue-specific promoter, a cell lineage-specific promoter, or a synthetic promoter.
[0210] In some implementations, the promoter used to express the miRNA hairpin can be the UBI promoter.
[0211] In some implementations, the promoter used to express the miRNA hairpin is the EF1α promoter, a derivative of the EF1α promoter, or a short EF1 promoter.
[0212] The preferred promoter for expressing miRNA hairpins is the EF1 short promoter.
[0213] In some embodiments of the present invention, the nucleic acid construct includes a promoter element configured to express a CD7-targeting peptide. The promoter element may be a promoter.
[0214] In some embodiments, the promoter configured to express the CD7-targeting peptide can be the PGK promoter, the EF1α promoter, a derivative of the EF1α promoter, or a short EF1 promoter.
[0215] In some embodiments, the miRNA and CD7-targeting peptide can be regulated by a single promoter.
[0216] In some embodiments, the miRNA and CD7-targeting peptide can be regulated by independent promoters. The independent promoters described herein are selected independently of each other and can therefore be of the same or different types.
[0217] In embodiments where the nucleic acid construct contains more than one miRNA, all miRNAs may be regulated by a single promoter, or each miRNA may be regulated by an independent promoter. The different promoters described herein are selected independently of each other and therefore may be of the same or different types.
[0218] In another embodiment of the nucleic acid construct containing more than one miRNA, the miRNAs can be grouped such that some miRNAs are regulated by one promoter while others are regulated by another promoter. For example, if a nucleic acid construct contains six miRNAs, four of the miRNAs may be regulated by one promoter and the other two by a second promoter; or, three of the miRNAs may be regulated by one promoter and the other three by a second promoter.
[0219] The expression of the target coding sequence can also be achieved using other viral, mammalian cell, or bacterial phage promoters known in the art, provided that the expression level is sufficient for the intended purpose.
[0220] An enhancer is a genetic element that can increase the transcriptional level of a promoter located at a distal position on the same DNA molecule. Enhancers are organized very similarly to promoters, consisting of multiple independent elements, each of which can bind to one or more transcription proteins.
[0221] The fundamental difference between enhancers and promoters lies in their operational characteristics. An enhancer region as a whole must be able to promote transcription at a certain distance, while a promoter region or its constituent elements do not necessarily possess this characteristic. On the other hand, a promoter must contain one or more elements capable of guiding the initiation of RNA synthesis at a specific location and in a specific direction, while enhancers do not possess these specificities. Promoters and enhancers often overlap or are adjacent to each other, and their modular organization is also very similar.
[0222] The following lists viral promoters, cellular promoters / enhancers, and inducible promoters / enhancers that can be used in this invention (Tables 5 and 6). Furthermore, any promoter / enhancer combination (e.g., combinations listed in the eukaryotic promoter database EPDB) can be used to drive the expression of CD7-binding peptides and / or miRNAs. Truncated promoters can also be used to drive expression. Eukaryotic cells are also able to support cytoplasmic transcription of certain bacterial promoters if a suitable bacterial polymerase is provided (whether as part of the delivery complex or as an additional gene expression construct).
[0223]
[0224] spacer
[0225] In some embodiments, the nucleic acid construct of the present invention may include spacers.
[0226] The presence of spacers appears to improve the knockdown efficiency of miRNAs (Stegmeier et al., 2005). Spacers can be any nucleotide sequence.
[0227] In some embodiments, the length of the spacer may be at least 50 nucleotides.
[0228] In other embodiments, the length of the spacer can be from 50 to 1,000 nucleotides.
[0229] In other embodiments, the length of the spacer can be 50 to 900, 50 to 800, 100 to 800, or 50 to 800 nucleotides.
[0230] In other embodiments, the length of the spacer is at least 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180 or 200 nucleotides.
[0231] In some implementations, the spacer is a GFP-derived spacer.
[0232] In a preferred embodiment, the spacer has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with SEQ ID NO: 141.
[0233] In some embodiments, the spacer comprises or is composed of SEQ ID NO: 141.
[0234]
[0235] Nucleic acid constructs can also include terminators as their elements. Such elements can increase the level of transcription products and minimize read-through of transcription from one expression cassette to other sequences.
[0236] Gene screening
[0237] In some embodiments of the present invention, the nucleic acid construct may contain a screening gene.
[0238] Such screening genes can cause recognizable changes in cells expressing the nucleic acid construct, thereby facilitating the identification of such cells.
[0239] Typically, adding drug screening biomarkers aids in cloning and screening transformants. For example, genes conferring resistance to neomycin, puromycin, hygromycin, dihydrofolate reductase (DHFR), guanine phosphoribosyltransferase (GPT), bleomycin, and histamine can all serve as useful screening biomarkers. Alternatively, enzymes such as herpes simplex virus thymidine kinase (tk) or chloramphenicol acetyltransferase (CAT) can be used. Immunological biomarkers can also be used. The specific screening biomarker employed is considered less critical, as long as it can be co-expressed with the nucleic acid encoding the gene product. Examples of other screening biomarkers are well known to those skilled in the art. In this embodiment, the screening biomarker is RQR8, tEGFR, or CD20.
[0240] In some embodiments, the screening gene is LNGFR, truncated epidermal growth factor receptor (tEGFR), tCD19, CD20 or truncated CD20 (tCD20), tCD34 or a derivative thereof.
[0241] Suicide gene or safety switch
[0242] In some embodiments, the nucleic acid constructs of the present invention may contain a suicide gene or a safety switch. In this document, the terms "suicide gene" and "safety switch" are used interchangeably.
[0243] These terms refer to genes that, when activated, can cause cell death, typically through targeted cytotoxic effects mediated by apoptosis or adaptive immune responses.
[0244] In some embodiments, the suicide gene or safety switch gene is selected from the group consisting of: herpes simplex virus thymidine kinase (HSV-tk), inducible caspase 9 (iCasp9), truncated epidermal growth factor receptor (tEGFR), RQR8, dihydrofolate reductase (DHFR), CD20 or truncated CD20 (tCD20), thymidine synthase (TYMS), and lenalidomide off-switch CAR molecules.
[0245] Internal ribosome entry site (IRES)
[0246] In some embodiments, the nucleic acid construct may include an internal ribosome entry site (IRES) to facilitate protein co-expression.
[0247] In one embodiment, the construct further includes a peptide cleavage site. In another embodiment, the peptide cleavage site is a 2A peptide. In yet another embodiment, the 2A peptide is selected from the group consisting of: 2A, P2A, T2A, E2A, F2A, BmCPV 2A, and BmIFV 2A.
[0248] Delivery of nucleic acid molecules and expression vectors
[0249] This invention envisions the delivery of nucleic acid constructs into cells. For example, nucleic acid constructs can be delivered into cells to prepare the engineered donor cells of this invention.
[0250] In some respects, vectors for delivering the nucleic acid constructs of the present invention can be constructed to enable the expression of these constructs in cells.
[0251] This invention includes DNA molecules, plasmids, or vectors containing the nucleic acid constructs of this invention.
[0252] In some embodiments, the carrier is an expression carrier.
[0253] In some embodiments, the expression vector is an adenovirus, adeno-associated virus, retrovirus, or lentiviral vector.
[0254] In an embodiment, expressing the nucleic acid construct of the present invention in cells includes transfecting the cells with a transposon comprising the nucleic acid construct, plasmid, or vector, optionally wherein the transposon is a Sleeping Beauty, piggyBac, or Tol2 transposon.
[0255] In some embodiments, the nucleic acid constructs, plasmids, or vectors of the present invention can be delivered to cells in the form of lipid nanoparticles (LNPs). The use of any form of LNP is contemplated herein.
[0256] The present invention also envisions implementing homologous targeted recombination (HDR) through CRISPR, TALE nuclease, zinc finger nuclease, lead editing (PASSIGE), and gene writing technologies.
[0257] In this embodiment, the cell is a human cell.
[0258] In one embodiment, the method is an in vivo method. In another embodiment, the method is an in vitro method. In yet another embodiment, the method is an ex vivo method.
[0259] In one embodiment, the method further includes transplanting the cells into an organism.
[0260] In an embodiment of the method, the cells are contained within a living organism.
[0261] In specific implementations, the following systems and methods can be used to deliver nucleic acids to the desired cell types.
[0262] Homologous recombination
[0263] In embodiments of the present invention, a vector encoding the nucleic acid construct of the present invention can be introduced into cells in a specific manner, such as through homologous recombination. Currently, methods for expressing genes in stem cells involve using viral vectors (e.g., lentiviral vectors) or transgenes randomly integrated into the genome. These methods have failed to achieve success, in part because randomly integrated vectors may activate or inhibit endogenous gene expression, and / or lead to transgene expression silencing. Homologous recombination at specific loci in the target genome can partially overcome the problems associated with random integration.
[0264] Homologous recombination (HR), also known as general recombination, is a type of genetic recombination present in all life forms, in which nucleotide sequences are exchanged between two similar or identical DNA strands. Since the mid-1980s, this technique has been the standard method for genome engineering in mammalian cells. The process involves multiple steps, including the physical breaking of DNA and its eventual rejoining. In nature, its most widespread use is repairing potentially fatal double-strand breaks in DNA. Furthermore, homologous recombination produces new combinations of DNA sequences during meiosis; meiosis is the process by which eukaryotes produce gametes such as sperm and eggs. These new DNA combinations constitute the genetic variation in offspring, enabling populations to adapt to changing environmental conditions over time. Homologous recombination is also involved in horizontal gene transfer, allowing the exchange of genetic material between different strains and species of bacteria and viruses. Homologous recombination is also used as a molecular biology technique to introduce genetic alterations into target organisms.
[0265] Homologous recombination can be used to target genome modifications. In mammalian cells, the efficiency of standard HR is only 10 times that of treated cells. -6 Up to 10 -9 (Capecchi, 1990). To improve HR efficiency, large nucleases or homing endonucleases, such as I-SceI, have been used. Both natural large nucleases and modified, target-specific large nucleases have been used to improve HR efficiency (Pingoud and Silva, 2007; Chevalier et al., 2002). Another approach to improving HR efficiency is to modify chimeric endonucleases with programmable DNA-specific domains (Silva et al., 2011). Zinc finger nucleases (ZFNs) are an example of such chimeric molecules, in which the zinc finger DNA-binding domain is fused with the catalytic domain of a type II S restriction endonuclease (such as FokI) (see review in Durai et al., 2005; PCT / US2004 / 030606). Another class of molecules with this specificity includes transcription activator-like effector (TALE) DNA-binding domains fused to the catalytic domain of type II S restriction endonucleases (such as FokI) (Miller et al., 2011; PCT / IB2010 / 000154). This invention also envisions the use of clustered regularly spaced short palindromic repeats (CRISPR) gene editing technology.
[0266] Nucleic acid delivery system
[0267] Those skilled in the art can construct vectors using standard recombination techniques (see, for example, Sambrook et al., 2001 and Ausubel et al., 1996, both incorporated herein by reference in their entirety). Vectors include, but are not limited to, plasmids, granules, viruses (bacteriophages, animal viruses, and plant viruses), and artificial chromosomes (e.g., YAC), such as retroviral vectors (e.g., vectors derived from Moloney mouse leukemia virus (MoMLV), MSCV, SFFV, MPSV, SNV, etc.), lentiviral vectors (e.g., derived from HIV-1, HIV-2, SIV, BIV, FIV, etc.), adenovirus (Ad) vectors (including adenovirus vectors with replication capability, replication-defective forms, and forms with the entire viral genome removed), adeno-associated virus (AAV) vectors, simian virus 40 (SV-40) vectors, bovine papillomavirus vectors, Epstein-Barr virus, herpesvirus vectors, vaccinia virus vectors, Harvey mouse sarcoma virus vectors, mouse mammary tumor virus vectors, and Rous sarcoma virus vectors.
[0268] Additional carrier
[0269] The present invention can also use plasmid- or liposome-based extrachromosomal vectors, i.e., augmentative vectors. Such augmentative vectors may include, for example, oriP-based vectors and / or vectors encoding EBV protein EBNA-1 derivatives. These vectors are capable of introducing larger DNA fragments into cells and maintaining them in an extrachromosomal form, wherein the DNA fragments replicate once per cell cycle, are efficiently distributed to daughter cells, and substantially do not elicit an immune response.
[0270] Specifically, EBNA-1 is the only viral protein required for replication of oriP-based expression vectors. Because EBNA-1 has developed an efficient mechanism to bypass the processing required for its antigen presentation onto MHC class I molecules, it does not trigger a cellular immune response (Levitskaya et al., 1997). Furthermore, EBNA-1 can act trans-enhance, thereby increasing the expression of clonal genes; in some cell lines, it can increase clonal gene expression by up to 100-fold (Langle-Rouault et al., 1998; Evans et al., 1997). Finally, these oriP-based expression vectors are relatively inexpensive to manufacture.
[0271] Other extrachromosomal vectors include vectors based on other lymphotropic herpesviruses. Lymphotropic herpesviruses are herpesviruses capable of replicating in lymphoblasts (such as human B lymphoblasts) and existing in plasmid form during certain stages of their natural life cycle. Herpes simplex virus (HSV) is not a “lymphotropic” herpesvirus. Exemplary lymphotropic herpesviruses include, but are not limited to, EBV, Kaposi's sarcoma-associated herpesvirus (KSHV), simian herpesvirus (HS), and Marek's disease virus (MDV). The use of other augmentative vector sources, such as yeast ARS, adenovirus, SV40, or bovine papillomavirus (BPV), is also envisioned.
[0272] Those skilled in the art can construct vectors using standard recombination techniques (see, for example, Maniatis et al., 1988 and Ausubel et al., 1994; both are incorporated herein by reference in their entirety).
[0273] The vector may also contain other components or functions to further modulate gene delivery and / or gene expression, or otherwise provide beneficial properties to target cells. For example, such other components may include components that affect the binding of the vector to cells or the targeting of cells (including components that mediate cell type-specific or tissue-specific binding); components that affect the uptake of the vector nucleic acid by cells; components that affect the intracellular localization of polynucleotides after uptake (such as reagents that mediate nuclear localization); and components that affect the expression of polynucleotides.
[0274] Such components may also include biomarkers, such as detectable and / or screening biomarkers, which can be used to detect or screen cells that take up the nucleic acid delivered by the vector and express that nucleic acid. Such components may be provided as a natural feature of the vector (e.g., using certain viral vectors with functions or components that mediate binding and uptake), or they may be conferred such functions by modifying the vector. Various such vectors are known in the art and are generally available. When maintained in a host cell, the vector can stably replicate as an autonomous structure during mitosis, integrate into the host cell genome, or be maintained in the nucleus or cytoplasm of the host cell.
[0275] Transposon-based systems
[0276] According to specific embodiments of the present invention, a transposon-transposase system can be used when introducing nucleic acids. The transposon-transposase system used can be the well-known Sleeping Beauty system, the Frog Prince transposon-transposase system (for a description of the latter, see, for example, EP1507865), or the TTAA-specific piggyback transposon system.
[0277] Transposons are DNA sequences that can move to different locations within the genome of a single cell; this process is called transposition. During this process, transposons can cause mutations and alter the amount of DNA in the genome. Transposons, formerly known as jumping genes, are examples of mobile genetic elements.
[0278] Mobile genetic elements come in various types and can be classified according to their transposition mechanisms. Type I mobile genetic elements, namely retrotransposons, first form RNA through transcription, then are reverse transcribed into DNA by reverse transcriptase, and finally insert themselves into another location in the genome, thus achieving self-replication. Type II mobile genetic elements, on the other hand, use transposases to move directly from one location to another, completing transposition through "cutting and pasting" within the genome.
[0279] Viral vector
[0280] In the preparation of recombinant viral vectors, non-essential genes are typically replaced with genes or coding sequences encoding heterologous (or non-native) proteins or nucleic acids. Viral vectors are expression constructs that utilize viral sequences to introduce nucleic acids and, if present, proteins into cells. Certain viruses are capable of infecting cells, or entering cells via pH-dependent or pH-independent mechanisms; they can integrate their genetic payload into the host cell genome; and they can stably and efficiently express viral genes. These characteristics make viruses attractive candidates for introducing exogenous nucleic acids into cells (e.g., mammalian cells). The following describes non-limiting examples of viral vectors that can be used to deliver nucleic acids involved in certain aspects of this invention.
[0281] Retroviruses are considered promising gene delivery vectors due to their ability to integrate their genes into the host genome, transfer large amounts of exogenous genetic material, infect a wide range of species and cell types, and package themselves in specific cell lines (Miller, 1992).
[0282] To construct retroviral vectors, nucleic acids are inserted into the viral genome to replace certain viral sequences, thereby producing replication-defective viruses. To generate viral particles, packaging cell lines are constructed containing the gag, pol, and env genes, but lacking long terminal repeats (LTRs) and packaging elements (Mann et al., 1983). After a recombinant plasmid containing cDNA, along with the retroviral LTR and packaging sequences, is introduced into a specific cell line (e.g., via calcium phosphate precipitation), the packaging sequences enable the RNA transcripts of the recombinant plasmid (i.e., the vector genome) to be packaged into viral particles, which are then secreted into the culture medium (Nicolas and Rubenstein, 1988; Temin, 1986; Mann et al., 1983). The culture medium containing the recombinant retrovirus is then harvested and optionally concentrated for gene transfer. Depending on the tropism of the envelope proteins used to coat the surface of the vector particles, retroviral vectors can infect a variety of cell types. However, integration and stable expression require host cell division (Paskind et al., 1975).
[0283] Lentivirals are complex retroviruses that, in addition to the common retroviral genes gag, pol, and env, contain other genes with regulatory or structural functions. Lentiviral vectors are well known in the art (see, for example, Naldini et al., 1996; Zufferey et al., 1997; Blomer et al., 1997; Giry-Laterriere et al., 2011; U.S. Patents 6,013,516 and 5,994,136).
[0284] Recombinant lentiviral vectors can infect non-dividing cells and can be used for in vivo and in vitro gene transfer and nucleic acid sequence expression. For example, U.S. Patent 5,994,136 (incorporated herein by reference) describes a recombinant lentivirus capable of infecting non-dividing cells, wherein suitable host cells are transfected with vectors carrying two or more packaging functions (i.e., gag, pol, and env) and rev and tat.
[0285] Nucleic acid delivery
[0286] When introducing the nucleic acid constructs of the present invention, any suitable nucleic acid delivery method can be used to transform cells, such as the methods described herein or methods known to those skilled in the art. Such methods include, but are not limited to: direct delivery of DNA, such as via in vitro transfection (Wilson et al., 1989; Nabel et al., 1989); delivery by injection (US Patent Nos. 5,994,624, 5,981,274, 5,945,100, 5,780,448, 5,736,524, 5,702,932, 5,656,610, 5,589,466, and 5,580,859, all incorporated herein by reference), including microinjection (Harland and Weintraub, 1985; US Patent No. 5,789,215, incorporated herein by reference); delivery by electroporation (US Patent No. 5,384,253, incorporated herein by reference; Tur-Kaspa et al., 1986; Potter et al., 1984); and delivery by calcium phosphate precipitation (Graham and VanDer). Eb, 1973; Chen and Okayama, 1987; Rippe et al., 1990); treatment with DEAE-dextran followed by polyethylene glycol treatment (Gopal, 1985); delivery via direct acoustic loading (Fechheimer et al., 1987); delivery via liposome-mediated transfection (Nicolau and Sene, 1982; Fraley et al., 1979; Nicolau et al., 1987; Wong et al., 1980; Kaneda et al., 1989; Kato et al., 1991); delivery via receptor-mediated transfection (Wu and Wu, 1987; Wu and Wu, 1988); delivery via particle bombardment (PCT application No. WO). U.S. Patents 5,610,042, 5,322,783, 5,563,055, 5,550,318, 5,538,877, and 5,538,880 (all incorporated herein by reference); delivery via co-oscillation with silicon carbide fibers (Kaeppler et al., 1990; U.S. Patents 5,302,523 and 5,464,765, all incorporated herein by reference); delivery via Agrobacterium-mediated transformation (U.S. Patents 5,591,616 and 5,563,055, all incorporated herein by reference); delivery via drying / inhibition-mediated DNA uptake (Potrykus et al., 1985); and any combination of the foregoing. By employing techniques such as these, stable or transient transformation of one or more organelles, one or more cells, one or more tissues, or one or more organisms can be achieved.
[0287] Liposome-mediated transfection
[0288] In some embodiments of the invention, the nucleic acid constructs of the invention may be encapsulated in lipid complexes, such as, for example, liposomes. Liposomes are vesicle structures characterized by a phospholipid bilayer and an internal aqueous medium. Multilayer liposomes have multiple lipid layers separated by an aqueous medium. Multilayer liposomes spontaneously form when phospholipids are suspended in an excess of aqueous solution. Before forming a closed structure, the lipid components undergo self-assembly rearrangement, encapsulating water and dissolved solutes between the lipid bilayers (Ghosh and Bachhawat, 1991). The use of nucleic acids complexed with Lipofectamine (GibcoBRL) or Superfect (Qiagen) is also considered. The amount of liposomes used can vary depending on the properties of the liposomes and the type of cells used. For example, approximately 5 to approximately 20 µg of carrier DNA per 1 million to 10 million cells may be considered.
[0289] Liposome-mediated delivery of nucleic acids and in vitro expression of exogenous DNA have achieved great success (Nicolau and Sene, 1982; Fraley et al., 1979; Nicolau et al., 1987). The feasibility of liposome-mediated delivery and expression of exogenous DNA in cultured chicken embryo cells, HeLa cells, and hepatocellular carcinoma cells has also been demonstrated (Wong et al., 1980).
[0290] In some embodiments of the invention, liposomes can form a complex with hemagglutination virus (HVJ). Studies have shown that this facilitates liposome fusion with the cell membrane and promotes the entry of liposome-encapsulated DNA into the cell (Kaneda et al., 1989). In other embodiments, liposomes can form a complex with, or be used in combination with, a nuclear non-histone chromosomal protein (HMG 1) (Kato et al., 1991). In other embodiments, liposomes can be complexed with, or used in combination with, both HVJ and HMG 1. In other embodiments, the delivery carrier may comprise a ligand and liposomes.
[0291] Electroporation
[0292] In some embodiments of the invention, nucleic acid constructs are introduced into organelles, cells, tissues, or organisms via electroporation. Electroporation involves subjecting a suspension of cells and DNA to a high-voltage discharge. This mechanical damage can increase the susceptibility of recipient cells to transformation. Furthermore, the amount of carrier used can vary depending on the nature of the cells used; for example, approximately 5 to approximately 20 µg of carrier DNA per 1 million to 10 million cells may be considered.
[0293] Electroporation has been quite successful in transfecting eukaryotic cells. For example, this method has been used to transfect the human κ immunoglobulin gene into mouse pre-B lymphocytes (Potter et al., 1984) and the chloramphenicol acetyltransferase gene into rat hepatocytes (Tur Kaspa et al., 1986).
[0294] Calcium phosphate
[0295] In other embodiments of the invention, the nucleic acid construct is introduced into cells using calcium phosphate precipitation. This technique has been used to transfect adenovirus 5 DNA into human KB cells (Graham and Van Der Eb, 1973). Furthermore, this method has been used to transfect neomycin marker genes into mouse L(A9), mouse C127, CHO, CV 1, BHK, NIH3T3, and HeLa cells (Chen and Okayama, 1987), and to transfect multiple marker genes into rat hepatocytes (Rippe et al., 1990).
[0296] DEAE-glucan
[0297] In another embodiment, the nucleic acid construct is delivered into cells first using DEAE-dextran and then polyethylene glycol. This method has been used to introduce reporter plasmids into mouse myeloma cells and erythroleukemia cells (Gopal, 1985).
[0298] Cell culture
[0299] Typically, cells (such as the engineered donor cells of this invention) are cultured in a culture medium, which is a nutrient-rich buffer solution that can sustain cell growth.
[0300] Culture media suitable for isolating, expanding, and differentiating stem cells according to the methods described herein include, but are not limited to, high-glucose Darwin-Modified Eijer's Medium (DMEM), DMEM / F-12, Liebovitz L-15, RPMI 1640, Eijer-Modified Darwin's Medium (IMDM), and Opti-MEM SFM (Invitrogen). Chemically defined media are also applicable, containing minimum essential media such as Eijer-Modified Darwin's Medium (IMDM) (Gibco) supplemented with human serum albumin, human ExCyte lipoprotein, transferrin, insulin, vitamins, essential and non-essential amino acids, sodium pyruvate, glutamine, and mitogens. As used herein, a mitogen is a reagent that stimulates cell division. This reagent can be a chemical substance, typically a form of protein, that induces cell division and triggers mitosis. In one embodiment, serum-free culture media, such as those described in U.S. Patent Application Serial Nos. 08 / 464,599 and WO96 / 39487, and the “complete culture medium” described in U.S. Patent No. 5,486,359, are considered for use in the methods described herein. In some embodiments, the culture medium is supplemented with 10% fetal bovine serum (FBS), autologous human serum, human AB serum, or platelet-rich plasma supplemented with heparin (2 U / ml). Cell cultures can be maintained in a CO2 atmosphere, for example, at a CO2 concentration of 5% to 12%, to maintain the pH of the culture medium, incubated in a humid environment at 37°C, and passaged to maintain cell confluence below 85%.
[0301] Methods for preparing engineered donor cells
[0302] The present invention provides a method for preparing engineered donor cells, the method comprising transfecting or transducing cells using the nucleic acid constructs of the present invention.
[0303] In some embodiments, the nucleic acid construct may be provided in the form of the DNA molecule, plasmid, or vector of the present invention.
[0304] The present invention also provides a method for preparing engineered donor cells from patient donors or healthy donors, the method comprising: (a) Collecting cells from a donor; (b) Transfecting or transducing the cells using the nucleic acid constructs, DNA molecules, plasmids, or vectors of the present invention; and (c) Express the nucleic acid construct.
[0305] The cells to be transfected or transduced can be any type of cell.
[0306] In some embodiments, the cell is a eukaryotic cell, such as a mammalian cell.
[0307] In some embodiments, the cells are immune effector cells.
[0308] In some embodiments, the immune effector cells are selected from the group consisting of αβ T cells, γδ T cells, tumor-infiltrating lymphocytes (TILS), TCR-engineered T cells, CAR T cells, NK cells, NK / T cells, regulatory T cells, mucosa-associated inert T cells (MAIT), monocytes, and macrophages.
[0309] In some embodiments, the cell is a T cell.
[0310] In some embodiments, the cells are CAR T cells.
[0311] In some embodiments, the cell is a stem cell or progenitor cell.
[0312] In some embodiments, the cells are pluripotent stem cells, such as embryonic stem cells and / or induced pluripotent stem cells.
[0313] In some embodiments, the cells are pluripotent stem cells, such as hematopoietic stem cells.
[0314] In some implementations, the cells may be derived from an object, such as a human object.
[0315] In some implementations, the human object may be a healthy human object.
[0316] In some implementations, the human subject may suffer from a disease. In this case, the "subject" may be referred to as a "patient".
[0317] This paper may employ any transfection or transduction method known in the art.
[0318] Composition
[0319] The present invention includes a composition comprising the engineered donor cells, nucleic acid constructs, antibodies, nucleic acid constructs, DNA molecules, plasmids, or vectors of the present invention.
[0320] In some embodiments, the composition may be a pharmaceutically acceptable composition.
[0321] In some embodiments, the composition may contain a pharmaceutically acceptable carrier, excipient, diluent, or salt.
[0322] Treatment
[0323] Any product of this invention, namely the engineered donor cells, nucleic acid constructs, DNA molecules, plasmids, vectors or compositions thereof, can be used to treat diseases.
[0324] It should be understood that treatments falling within the scope of this invention include in vivo delivery of the product of this invention. In vitro delivery of the product of this invention for the purpose of preparing engineered donor cells can also be considered a treatment.
[0325] Therefore, the present invention is intended to use the engineered donor cells, nucleic acid constructs, DNA molecules, plasmids, vectors or compositions of the present invention in methods for treating diseases.
[0326] The present invention also contemplates a method for treating a disease, comprising administering to a subject in need the engineered donor cells, nucleic acid constructs, DNA molecules, plasmids, vectors, or compositions of the present invention.
[0327] The present invention also considers using the engineered donor cells, nucleic acid constructs, DNA molecules, plasmids, vectors or compositions of the present invention to prepare drugs for treating diseases.
[0328] Within the scope of this invention, the disease can be any disease that a person skilled in the art believes can be treated by the engineered donor cells, nucleic acid constructs, DNA molecules, plasmids, vectors or compositions of this invention.
[0329] The term "treatment" as used herein is intended to include therapeutic interventions and curative treatments that can improve a disease. Furthermore, it also encompasses preventative uses; therefore, treatment may include treating an individual who is susceptible to a disease or otherwise shows signs of progression to a disease state, even if the individual does not necessarily have symptoms or a clinical diagnosis of the disease.
[0330] According to the present invention, the object to be treated can be any object, including but not limited to human objects, such as adult, adolescent or infant human objects.
[0331] In some implementations, the disease to be treated may be selected from the following group: cancer, infectious diseases, autoimmune diseases, or genetic diseases.
[0332] In some implementations, the cancer may be a T-cell malignancy, such as leukemia or lymphoma, an NK-cell malignancy, or CD7-positive acute myeloid leukemia (AML).
[0333] Recent observations have revealed that up to 30% of myeloid cell patients express CD7. These patients also have a poorer response to chemotherapy and standard treatment (https: / / pubmed.ncbi.nlm.nih.gov / 30391141 / ).
[0334] In some implementations, the disease may be a disease associated with CD7+ cells.
[0335] In some implementations, the CD7+ cell-related disease may be systemic sclerosis (https: / / pubmed.ncbi.nlm.nih.gov / 38123919 / ).
[0336] The numbered embodiments of the present invention
[0337] The following lists a set of numbered embodiments of the present invention. Although these embodiments provide specific implementations of the invention, they should not be construed as limiting the scope of the invention.
[0338] 1. An engineered donor cell expressing a CD7-targeting peptide and one or more microRNAs (miRNAs), said miRNAs functionally downregulating a target in the cell.
[0339] 2. The engineered donor cell according to Embodiment 1, wherein the CD7-targeting polypeptide specifically binds to CD7, optionally wherein the CD7-targeting polypeptide is an engineered T-cell receptor targeting CD7, optionally, a chimeric antigen receptor (CAR) targeting CD7.
[0340] 3. The engineered donor cell according to embodiment 1 or 2, wherein the miRNA enhances the cell's amplification capacity, reduces the cell's allogeneic reactivity, reduces the immune system's rejection of the cell, reduces the cell's lymphocyte depletion, reduces cell cannibalism, and / or enhances the cell's efficacy.
[0341] 4. The engineered donor cells according to any one of embodiments 1 to 3, wherein the miRNA functionally downregulates TCR, CD7, HLA-I and / or HLA-II.
[0342] 5. The engineered donor cell according to any one of embodiments 1 to 4, wherein the miRNA functionally downregulates CD7 by inhibiting CD7 expression.
[0343] 6. The engineered donor cell according to any one of embodiments 1 to 5, wherein the miRNA functionally downregulates TCR by inhibiting the expression of TCRα, TCRβ, CD3δ, CD3γ, CD3ε and / or CD3ζ.
[0344] 7. The engineered donor cells according to any one of embodiments 1 to 6, wherein the miRNA functionally downregulates HLA-I by inhibiting the expression of one or more of HLA-I peptide, B2M, NLRC5, TAP1, TAP2, TAPBP, RFX5, RFXANK and / or RFXAP.
[0345] 8. The engineered donor cell according to any one of embodiments 1 to 7, wherein the miRNA functionally downregulates HLA-II by inhibiting the expression of one or more of HLA-II peptide, CIITA, RFX5, RFXANK and / or RFXAP.
[0346] 9. The engineered donor cells according to any one of embodiments 1 to 8, wherein the miRNA is functionally downregulated by inhibiting the expression of CD5, B2M, CD3ζ, CD3ε, CD3δ, CD3γ, TCRα, TCRβ, CIITA, RFX5, RFXANK, RFXAP, TIM-3, PD-1, CD52, TIGIT, LAG-3, CTLA-4, DNMT3A, NR4A3, PRDM1, TGFBR2, REGNASE-1, ROQUIN-1, CCR5 and / or GM-CSF.
[0347] 10. The engineered donor cell according to any one of embodiments 1 to 9 further upregulates one or more surface-expressed polypeptides involved in immune signal transduction, optionally upregulating them by expressing transcripts of said polypeptides.
[0348] 11. The engineered donor cells according to Embodiment 10, wherein the upregulated surface-expressed peptides involved in immune signal transduction are non-classical HLA class I peptides, CD47 and / or PD-L1.
[0349] 12. The engineered donor cell according to any one of embodiments 1 to 11, wherein the surface-expressed non-classical HLA class I molecules are upregulated, while the surface-expressed HLA class I molecules are downregulated.
[0350] 13. The engineered donor cell according to embodiment 12, wherein the non-classical HLA class I polypeptide is a genetically modified HLA-E, HLA-G or HLA-F polypeptide.
[0351] 14. The engineered donor cells according to any one of embodiments 1 to 13, wherein the surface-expressed CAR is upregulated and the surface-expressed TCR is downregulated.
[0352] 15. The engineered donor cell according to any one of embodiments 1 to 14 further expresses a safety switch gene or a suicide gene.
[0353] 16. A nucleic acid construct comprising a sequence encoding a polypeptide targeting CD7 and one or more miRNA hairpins.
[0354] 17. The nucleic acid construct according to embodiment 16, comprising miRNA hairpins, wherein the miRNA hairpins: (a) The target is a sequence selected from those having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with any of the sequences in SEQ ID NO: 1 to 128 or SEQ ID NO: 282 to 293; and / or (b) includes a sequence selected from any of the sequences in SEQ ID NO: 142 to 281 that has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity.
[0355] 18. The nucleic acid construct according to embodiment 16 or 17, wherein the CD7-targeting polypeptide comprises a polypeptide encoded by a polynucleotide sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with SEQ ID NO: 129, SEQ ID NO: 130, SEQ ID NO: 131, SEQ ID NO: 132, SEQ ID NO: 133, or SEQ ID NO: 134, and / or wherein the CD7-targeting polypeptide comprises a polypeptide sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with SEQ ID NO: 135, SEQ ID NO: 136, SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 139, or SEQ ID NO: 140.
[0356] 19. The nucleic acid construct according to any one of embodiments 16 to 18, wherein the first miRNA hairpin has two copies and / or the second miRNA hairpin has two copies.
[0357] 20. The nucleic acid construct according to any one of embodiments 16 to 19, wherein the first miRNA hairpin has three copies and / or the second miRNA hairpin has three copies.
[0358] 21. A nucleic acid construct according to any one of embodiments 16 to 20, wherein the construct comprises at least two different miRNA hairpins that target different regions of the same transcript.
[0359] 22. A nucleic acid construct according to any one of embodiments 16 to 21, wherein the construct comprises at least two different miRNA hairpins that target different transcripts of the same gene.
[0360] 23. A nucleic acid construct according to any one of embodiments 16 to 22, wherein the construct comprises at least two different miRNA hairpins that target different splice variants of the same gene.
[0361] 24. The nucleic acid construct according to any one of embodiments 16 to 23, further comprising a promoter element configured to express the miRNA hairpin, wherein optionally the promoter element is a promoter.
[0362] 25. The nucleic acid construct according to embodiment 24, wherein the promoter is a eukaryotic promoter, and optionally wherein the eukaryotic promoter is a Pol II or Pol III promoter.
[0363] 26. The nucleic acid construct according to embodiment 24, wherein the promoter is an inducible promoter, a tissue-specific promoter, a cell lineage-specific promoter, or a synthetic promoter.
[0364] 27. The nucleic acid construct according to embodiment 24, wherein the promoter is the UBI promoter.
[0365] 28. The nucleic acid construct according to embodiment 24, wherein the promoter is an EF1α promoter, a derivative of the EF1α promoter, or a short EF1 promoter, preferably wherein the promoter is a short EF1 promoter.
[0366] 29. The nucleic acid construct according to any one of embodiments 16 to 28, further comprising a promoter element configured to express the target CD7 polypeptide, wherein optionally the promoter element is a promoter.
[0367] 30. The nucleic acid construct according to embodiment 29, wherein the promoter configured to express the target CD7 polypeptide is a PGK promoter, an EF1α promoter, a derivative of the EF1α promoter, or a short EF1 promoter.
[0368] 31. The nucleic acid construct according to any one of embodiments 16 to 30, further comprising a spacer, wherein optionally the spacer comprises an enhancer; further optionally, wherein the spacer is an enhancer.
[0369] 32. The nucleic acid construct according to embodiment 31, wherein the length of the spacer is at least 50 nucleotides.
[0370] 33. The nucleic acid construct according to embodiment 31, wherein the length of the spacer is 50 to 1,000 nucleotides.
[0371] 34. The nucleic acid construct according to embodiment 31, wherein the length of the spacer is 50 to 900, 50 to 800, 100 to 800, or 50 to 800 nucleotides.
[0372] 35. The nucleic acid construct according to embodiment 31, wherein the length of the spacer is at least 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180 or 200 nucleotides.
[0373] 36. The nucleic acid construct according to any one of embodiments 31 to 35, wherein the spacer is a GFP sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with SEQ ID NO: 141.
[0374] 37. The nucleic acid construct according to any one of embodiments 31 to 36, wherein the spacer is located between the promoter configured to express the miRNA hairpin and the miRNA hairpin.
[0375] 38. The nucleic acid construct according to any one of embodiments 31 to 37, wherein the spacer is heterologous to the promoter element.
[0376] 39. The nucleic acid construct according to any one of embodiments 31 to 38, wherein the spacer comprises an encoded open reading frame.
[0377] 40. The nucleic acid construct according to any one of embodiments 16 to 39, wherein at least two miRNA hairpins are separated by an insert sequence.
[0378] 41. The nucleic acid construct according to any one of embodiments 16 to 40, wherein the CD7-targeting polypeptide specifically binds to CD7, optionally wherein the CD7-targeting polypeptide is an engineered T-cell receptor targeting CD7, optionally a CD7-targeting CAR.
[0379] 42. The nucleic acid construct according to any one of Embodiments 16 to 41, wherein the sequence encoding the polypeptide targeting CD7 comprises a polynucleotide sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with SEQ ID NO: 129, SEQ ID NO: 130, SEQ ID NO: 131, SEQ ID NO: 132, SEQ ID NO: 133, or SEQ ID NO: 134; and / or wherein the polypeptide targeting CD7 comprises a polypeptide sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with SEQ ID NO: 135, SEQ ID NO: 136, SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 139, or SEQ ID NO: 140.
[0380] 43. The nucleic acid construct according to any one of embodiments 16 to 42, wherein the miRNA hairpin is controlled by a first promoter and the sequence encoding a polypeptide targeting CD7 is controlled by a second promoter, or wherein both the miRNA hairpin and the sequence encoding a polypeptide targeting CD7 are controlled by a single promoter.
[0381] 44. The nucleic acid construct according to any one of embodiments 16 to 43, wherein the construct further comprises a screening gene.
[0382] 45. The nucleic acid construct according to embodiment 45, wherein the screening gene is LNGFR, truncated endothelial growth factor receptor (tEGFR), tCD19, CD20 or truncated CD20 (tCD20), tCD34 or a derivative thereof.
[0383] 46. The nucleic acid construct according to any one of embodiments 16 to 45, wherein the construct further comprises a sequence encoding a suicide gene or a safety switch gene.
[0384] 47. The nucleic acid construct according to embodiment 46, wherein the suicide gene or safety switch gene is selected from the group consisting of: herpes simplex virus thymidine kinase (HSV-tk), inducible caspase 9 (iCasp9), truncated endothelial growth factor receptor (tEGFR), RQR8, dihydrofolate reductase (DHFR), CD20 or truncated CD20 (tCD20), thymidine synthase (TYMS), and lenalidomide off-switch CAR molecules.
[0385] 48. The nucleic acid construct according to any one of embodiments 16 to 47, wherein the construct further comprises an internal ribosome entry site (IRES).
[0386] 49. A DNA molecule, plasmid, or vector comprising a nucleic acid construct according to any one of embodiments 16 to 48, wherein the vector is optionally an expression vector, and wherein the expression vector is optionally an adenovirus, adeno-associated virus, retrovirus, or lentiviral vector.
[0387] 50. A method for preparing engineered donor cells, comprising transfecting or transducing cells using a nucleic acid construct, DNA molecule, plasmid, or vector according to any one of embodiments 16 to 49.
[0388] 51. A method for preparing engineered donor cells from a patient donor or a healthy donor, comprising: (a) Collecting cells from a donor; (b) Transfecting or transducing the cells using the nucleic acid construct, DNA molecule, plasmid, or vector according to any one of embodiments 16 to 49; and (c) Express the nucleic acid construct.
[0389] 52. The method according to embodiment 50 or 51, wherein the engineered donor cell is a T cell.
[0390] 53. The method according to any one of embodiments 50 to 52, wherein the nucleic acid construct, DNA molecule, plasmid or vector downregulates the TCR peptide and upregulates the CD7-targeting CAR peptide, wherein the engineered donor cell is a CAR-T cell.
[0391] 54. An engineered donor cell that can be obtained or acquired by the method according to any one of embodiments 50 to 53.
[0392] 55. A cell comprising a nucleic acid construct, DNA molecule, plasmid, or vector according to any one of embodiments 1 to 49, wherein optionally the cell is an engineered donor cell.
[0393] 56. An engineered donor cell according to any one of embodiments 1 to 15, 54 or 55, wherein the engineered donor cell is a eukaryotic cell, and optionally wherein the engineered donor cell is a mammalian cell.
[0394] 57. An engineered donor cell according to any one of embodiments 1 to 15 or 54 to 56, wherein the engineered donor cell is an immune effector cell.
[0395] 58. The engineered donor cell according to embodiment 57, wherein the immune effector cell is selected from the group consisting of: αβ T cells, γδ T cells, tumor-infiltrating lymphocytes (TILS), TCR-engineered T cells, CAR T cells, NK cells, NK / T cells, regulatory T cells, mucosa-associated inert T cells (MAIT), monocytes, and macrophages.
[0396] 59. The engineered donor cell according to embodiment 58, wherein the immune effector cell is a CAR-T cell.
[0397] 60. An engineered donor cell according to any one of embodiments 1 to 15 or 54 to 56, wherein the engineered donor cell is a stem cell or progenitor cell.
[0398] 61. The engineered donor cell according to embodiment 60, wherein the engineered donor cell is a pluripotent stem cell, such as an embryonic stem cell and / or an induced pluripotent stem cell.
[0399] 62. The engineered donor cell according to embodiment 60, wherein the engineered donor cell is a pluripotent stem cell, such as a hematopoietic stem cell.
[0400] 63. An engineered donor cell according to any one of embodiments 1 to 15 or 54 to 56, wherein the engineered donor cell is a differentiated cell.
[0401] 64. A composition comprising engineered donor cells according to any one of embodiments 1 to 15 or 54 to 63, optionally further comprising a pharmaceutically acceptable carrier, excipient, diluent, or salt.
[0402] 65. A method for depleting CD7+ cells in vitro, ex vivo, or in vivo, comprising contacting the CD7+ cells with engineered donor cells or compositions according to any one of embodiments 1 to 15 or 54 to 64.
[0403] 66. A method of using an engineered donor cell, nucleic acid construct, DNA molecule, plasmid, vector, or composition according to any one of embodiments 1 to 49 or 54 to 64 for treating a disease.
[0404] 67. A method of treating a disease, comprising administering to a subject in need an engineered donor cell, nucleic acid construct, DNA molecule, plasmid, vector, or composition according to any one of embodiments 1 to 49 or 54 to 64.
[0405] 68. An engineered donor cell, nucleic acid construct, DNA molecule, plasmid, vector, or composition according to any one of embodiments 1 to 49 or 54 to 64, used to prepare a medicament for treating a disease.
[0406] 69. The method according to any one of embodiments 66 to 68, wherein the disease is selected from the group consisting of cancer, infectious diseases, autoimmune diseases, or hereditary diseases.
[0407] 70. The method according to embodiment 69, wherein the cancer is a T-cell malignancy, such as leukemia or lymphoma.
[0408] 71. The method according to any one of embodiments 66 to 70, wherein the disease is a disease related to CD7+ cells.
[0409] 72. A miRNA hairpin, wherein the miRNA hairpin targets a sequence selected from the following sequences having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with any one of SEQ ID NO: 1 to 128 or 282–293.
[0410] 73. A miRNA hairpin, wherein the miRNA hairpin comprises a sequence selected from the following sequences having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with any one of SEQ ID NO: 142 to 281.
[0411] 74. A VHH antibody or antibody fragment, wherein the VHH antibody or antibody fragment targets a polypeptide sequence, the polypeptide sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with any one of SEQ ID NO: 135 to 140.
[0412] 75. An engineered donor cell or nucleic acid construct substantially as described herein and shown with reference to the accompanying drawings.
[0413] Example
[0414] The following examples are intended to illustrate preferred embodiments of the present invention. Those skilled in the art should understand that the techniques disclosed in the following examples are techniques that the inventors have found well suitable for implementing the present invention, and therefore can be considered as preferred methods for implementing the present invention. However, those skilled in the art should understand from this disclosure that many changes can be made to the specific embodiments disclosed without departing from the spirit and scope of the present invention, while still obtaining the same or similar results.
[0415] Example 1
[0416] The preparation of gene silencing constructs requires: (i) target sequence design; (ii) molecular cloning to construct single-hairpin miRNA constructs and prepare lentiviral vectors; and (iii) gene modification of target cells and evaluation of gene / protein silencing effects using appropriate readout methods. Subsequently, multi-hairpin miRNA constructs can be constructed using the optimal target sequence, and their maximum gene silencing efficiency can be evaluated in a similar manner. After developing the optimal gene silencing construct, it is integrated into a CAR-expressing construct for further validation and functional testing in CAR T-cell products.
[0417] In developing novel CAR constructs, single-domain, heavy-chain-only conjugates (VHHs) are used as the target portion of the CAR. Compared to traditionally used single-chain variable fragments (scFvs), single-domain conjugates offer significant advantages in CAR engineering, including: (i) higher stability because there is no need to assemble two different variable chains; and (ii) a size reduction of up to 40% (15 kDa vs. 25 kDa), enabling more compact payloads, improved vector preparation, and more efficient engineering of target cells. Specifically, fully humanized VHH conjugates (Moutel et al., 2016) are used in CAR design, which reduces the likelihood of CAR immunogenicity and consequently reduces the risk of host rejection of allogeneic CAR T cells during initial and subsequent repeated administrations.
[0418] Target sequence design
[0419] An internally developed workflow was used to design target sequences for integration into the miRNA structure. This workflow prioritizes the optimal gene silencing target sequences based on a pre-defined set of computational features. The main body of the workflow was developed in Python, with reference sequences taken from the current version of Ensembl. The potential / probability of gene silencing was predicted by evaluating various molecular features of each candidate target sequence, including but not limited to the presence of specific nucleotide compositions, transcript availability, and the number of inverted repeat sequences. Sequence prioritization was based on factors such as identifying conserved regions in the target transcript, ranking each target sequence separately, and reducing the risk of potential off-target gene silencing (based on sequence identity assessment between the target sequence and the target cell transcriptome). The tag “TARGET NAME_T#” was used to refer to the target sequences on the gene mRNA and the corresponding miRNAs targeting these sequences.
[0420] Discovery of VHH conjugates
[0421] Anti-human CD7 (hCD7) VHHs were discovered using a synthetic antibody library containing 3 billion VHHs. Three rounds of phage display screening were performed using biotinylated hCD7 to identify VHHs that recognize unadsorbed, native antigens. The screened VHHs were then validated using non-adsorbed phage ELISA and non-adsorbed inducible ELISA.
[0422] Molecular cloning
[0423] The preferred target sequence was synthesized into the mirGE backbone by a third-party manufacturer. Single mirGE sequences were cloned using LR Clonase II. The mirGE pENTR plasmid, the elongation factor 1 short promoter (pENTR-L4-EFs-L1R) plasmid, and the lentiviral vector target cassette (pCWX-R4dESTR2-PC) containing the mCherry reporter gene or CAR molecule were cloned into the same plasmid. Restriction endonuclease digestion mapping and DNA sequencing confirmed successful cloning of all constructs.
[0424] Lentiviral vector and titer determination
[0425] Lentiviral vectors carrying the mCherry reporter gene were prepared by transfecting HEK293T cells with a transfer plasmid carrying the gene silencing construct, along with lentiviral packaging plasmids (PAX2) and envelope plasmids (VSVg). Cell culture medium was replenished after 4–6 hours of culture, followed by harvesting the medium at 24 hours to harvest viral particles. Lentiviral vectors carrying the CAR construct were prepared by transfecting viral production cells (ThermoFisher) with a transfer plasmid carrying the gene silencing construct, along with lentiviral packaging plasmids (PAX2) and envelope plasmids (VSVg). These viral production cells were derived from the HEK293F cell line. Cell culture medium was harvested 48 hours post-transfection to harvest viral particles. For all lentiviral vectors, the culture medium was harvested and filtered to remove cell debris, followed by enrichment of viral particles using PEG-It viral precipitation solution (System Biosciences) according to the manufacturer's instructions. The final aliquots of concentrated lentiviral vectors were stored at -80°C. Functional viral vector titers were assessed by transducing HT1080 cells at a series of dilutions and measuring the percentage of cells expressing mCherry or RQR8 reporter genes.
[0426] Cells and cell lines
[0427] Expression and silencing of all gene constructs were assessed in primary T cells. The primary T cells were obtained from anonymized white blood cell samples provided by the Transfusion Center of the University Hospital of Geneva, Switzerland. Peripheral blood mononuclear cells (PBMCs) were isolated using the Ficoll method, followed by T cell isolation using the EasySep™ Human T Cell Isolation Kit (StemCell), and then aliquoted and cryopreserved in liquid nitrogen.
[0428] Gene delivery and CAR T cell preparation
[0429] Frozen T cells were thawed and cultured in T cell culture medium (X vivo, 5% human serum, 1% penicillin / streptomycin), supplemented with IL-7 and IL-15 (10 ng / mL each), and activated using CD3 / CD28 Dyna beads according to the manufacturer's instructions. 24–48 hours after activation, T cells were transduced using lentiviral vectors carrying miRNA gene silencing constructs (for mirGE selection) and lentiviral vectors carrying miRNA gene silencing and CAR expression constructs (for CAR T cell preparation). Transduction was performed at high cell density volumes (2 million cells / mL in standard culture plates for mirGE selection, and 1 million cells / mL in GREX culture plates for CAR T cell preparation). For mirGE selection, the medium was replaced with fresh medium 24 hours after transduction, and thereafter every other day to maintain a T cell culture density of 1 million cells / mL for at least 5 days, after which the silencing of the target gene was assessed. For CAR T cell preparation, culture medium was added to the wells to replenish the volume 24 hours after transduction. Eight days after transduction, the cells were reseeded into new GREX culture plates (500,000 to 1,000,000 cells in 24-well GREX plates and 5,000,000 to 15,000,000 cells in 6-well GREX plates). When reseeding cells in 24-well GREX plates, half of the culture medium was replaced with fresh medium on day 12. For CAR T cell preparation, TCR depletion was performed on day 15 after transduction (using the EasySep™ Human TCR α / β Depletion Kit, StemCell), followed by freezing and storage in liquid nitrogen. During this preparation process, silencing, transduction status, and markers of memory, depletion, and activation were assessed by flow cytometry on days 5 and 17 after transduction and after thawing.
[0430] Flow cytometry and gene silencing assessment
[0431] For cells used for mirGE screening, flow cytometry analysis was performed on day 5 post-transduction; for CAR T cells, analysis was performed on days 5 and 17 post-transduction, and after thawing. Cells were harvested, washed, and resuspended in staining buffer (EasySep™ Human TCR α / β Depletion Kit (Miltenyi Biotec), 5% BSA), and stained with appropriate antibodies for 10–30 minutes to assess cell surface expression. After staining, cells were washed with staining buffer, resuspended in staining buffer, and cell surface expression was assessed by flow cytometry. Data were exported to FlowJo for analysis. To calculate gene silencing levels, the percentage of target-positive cells and changes in median fluorescence intensity (MFI) were assessed. Normalization included comparing expression levels within the sample (modified cells vs. unmodified cells), followed by calculating expression levels relative to control transduced cells.
[0432] Cytotoxicity assay
[0433] MOLT-4 (ATCC CRL-1582) and SUP-T1 (ATCC CRL-192) cell lines were purchased from ATCC. Tumor cells stained with CellTrace violet (Thermo Fisher Scientific) or stably expressing GFP were mixed with untransduced T cells or CAR T cells at an effector-to-target cell ratio of 1:1, 1:3, or 1:9. For short-term killing assays, the number of tumor cells and T cells was assessed by flow cytometry at 24, 48, and 72 hours. For repeated killing assays, the number of tumor cells and T cells was assessed by flow cytometry every 3–4 days. At each time point and when tumor cells were removed, the same number of new tumor cells as initially seeded were added to the T cells.
[0434] In vivo tolerance model
[0435] Non-obese diabetic (NOD)-Cg-Prkdcscid112rgtml Wjl / SzJ (NSG) mice aged 7–9 weeks were purchased from Charles River UK. All procedures were performed in accordance with the UK Animal Science Procedures Act 1986 (ASPA). CAR T cells were prepared according to the aforementioned method. Each mouse (weighing ≥15 g at the start of the study) received a single intravenous injection of 7.5 × 10⁻⁶ Cg-Prkdcscid112rgtml Wjl / SzJ (NSG) via the tail vein. 6CAR T cells were injected in a total volume of 100 µL. Mice were monitored daily for general health, behavior, and signs of adverse reactions. Body weight was measured and recorded daily as an indicator of tolerability. Relative body weight was expressed as a percentage of initial body weight on day 0 (baseline). Animals were followed up for a total of 15 days post-injection.
[0436] Tumor cell in vivo implantation model
[0437] Non-obese diabetic (NOD)-Cg-Prkdcscid112rgtml Wjl / SzJ (NSG) mice aged 7–9 weeks were purchased from Charles River Laboratories, UK. All procedures were performed in accordance with the UK Animal Science Procedures Act 1986 (ASPA). Mice were first intravenously injected with 0.3 × 10⁻⁶ mmol / L of 0.3 × 10⁻⁶ mmol / L. 6 Five days later, a single injection of 0.2 × 10⁶ CCRF-CEM / GFP-ffluc cells was administered. 6 1.5 × 10 6 Or 6.5 × 10 6 One miCAR7 T cell, or 6.4 × 10 6 Mice were injected intraperitoneally with 150 mg / kg of miCAR19 T cells twice a week starting from day 4. Bioluminescence signals were recorded using an IVIS Spectrum CT imaging system (Perkin Elmer) to monitor tumor burden. Total luminescence signals were visualized and quantitatively analyzed using LivingImage software (Caliper LS, USA).
Claims
1. An engineered donor cell expressing a CD7-targeting peptide and one or more microRNAs (miRNAs) that functionally downregulate the target in the cell.
2. The engineered donor cell according to claim 1, wherein the CD7-targeting polypeptide specifically binds to CD7, and optionally wherein the CD7-targeting polypeptide is an engineered T-cell receptor that targets CD7, or optionally a chimeric antigen receptor (CAR) that targets CD7.
3. The engineered donor cells according to claim 1 or 2, wherein the miRNA functionally downregulates TCR, CD7, HLA-I and / or HLA-II.
4. The engineered donor cell according to any one of claims 1 to 3, wherein the miRNA functionally downregulates CD7 by inhibiting CD7 expression.
5. The engineered donor cells according to any one of claims 1 to 4, wherein the miRNA is functionally downregulated by inhibiting the expression of CD5, B2M, CD3z, CD3e, CD3d, CD3g, TCRRa, TCRb, CIITA, RFX5, RFXANK, RFXAP, TIM-3, PD-1, CD52, TIGIT, LAG-3, CTLA-4, DNMT3A, NR4A3, PRDM1, TGFBR2, REGNASE-1, ROQUIN-1, CCR5 and / or GM-CSF.
6. The engineered donor cell according to any one of claims 1 to 5, further expressing a safety switch gene or a suicide gene.
7. A nucleic acid construct comprising a sequence encoding a CD7-targeting polypeptide and one or more miRNA hairpins.
8. The nucleic acid construct according to claim 8, comprising miRNA hairpins, wherein the miRNA hairpins are: (a) The target is a sequence selected from those having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with any of the sequences in SEQ ID NO: 1 to 128 or SEQ ID NO: 282 to 293; and / or (b) includes a sequence selected from any of the sequences in SEQ ID NO: 142 to 281 that has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity.
9. The nucleic acid construct according to claim 7 or 8, wherein the CD7 targeting polypeptide comprises a polypeptide encoded by a polynucleotide sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with SEQ ID NO: 129, SEQ ID NO: 130, SEQ ID NO: 131, SEQ ID NO: 132, SEQ ID NO: 133, or SEQ ID NO: 134; and / or wherein the CD7 targeting polypeptide comprises a polypeptide sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with SEQ ID NO: 135, SEQ ID NO: 136, SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 139, or SEQ ID NO:
140.
10. The nucleic acid construct according to any one of claims 7 to 9, further comprising a promoter element configured to express the miRNA hairpin, optionally wherein the promoter element is a promoter and / or the nucleic acid construct further comprising a promoter element configured to express the CD7 targeting peptide, optionally wherein the promoter element is a promoter.
11. The nucleic acid construct according to any one of claims 7 to 10, further comprising a spacer, optionally wherein the spacer comprises an enhancer, and further optionally wherein the spacer is an enhancer.
12. The nucleic acid construct according to claim 11, wherein the spacer is a GFP sequence, and the GFP sequence has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with SEQ ID NO:
141.
13. The nucleic acid construct according to any one of claims 7 to 12, wherein the CD7-targeting polypeptide specifically binds to CD7, optionally wherein the CD7-targeting polypeptide is an engineered T-cell receptor targeting CD7, optionally a CAR targeting CD7.
14. The nucleic acid construct according to any one of claims 7 to 13, wherein, The sequence encoding the CD7-targeting polypeptide comprises a polynucleotide sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with SEQ ID NO: 129, SEQ ID NO: 130, SEQ ID NO: 131, SEQ ID NO: 132, SEQ ID NO: 133, or SEQ ID NO: 134; and / or wherein the CD7-targeting polypeptide comprises a polypeptide sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with SEQ ID NO: 135, SEQ ID NO: 136, SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 139, or SEQ ID NO:
140.
15. The nucleic acid construct according to any one of claims 7 to 14, wherein the construct further comprises a sequence encoding a suicide gene or a safety switch gene.
16. The nucleic acid construct according to claim 15, wherein the suicide gene or safety switch gene is selected from the group consisting of: herpes simplex virus thymidine kinase (HSV-tk), inducible caspase 9 (iCasp9), truncated endothelial growth factor receptor (tEGFR), RQR8, dihydrofolate reductase (DHFR), CD20 or truncated CD20 (tCD20), thymidine synthase (TYMS), and lenalidomide off-switch CAR molecules.
17. A DNA molecule, plasmid, or vector comprising a nucleic acid construct as described in any one of claims 7 to 16, wherein the vector is optionally an expression vector, and wherein the expression vector is optionally an adenovirus, adeno-associated virus, retrovirus, or lentiviral vector.
18. A method for preparing engineered donor cells, comprising transfecting or transducing the cells using a nucleic acid construct, DNA molecule, plasmid, or vector as described in any one of claims 7 to 17.
19. A method for preparing engineered donor cells from a patient donor or a healthy donor, comprising: (a) Collecting cells from the donor; as well as (b) Transfecting or transducing the cells using any of the nucleic acid constructs, DNA molecules, plasmids, or vectors as described in any one of claims 7 to 18; and (c) Express the nucleic acid construct.
20. An engineered donor cell that can be obtained or acquired by the method of claim 18 or 19.
21. The engineered donor cell of claim 20, wherein the immune effector cell is selected from the group consisting of: αβ T cells, γδ T cells, tumor-infiltrating lymphocytes (TILS), TCR-engineered T cells, CAR T cells, NK cells, NK / T cells, regulatory T cells, mucosa-associated inert T cells (MAIT), monocytes, and macrophages.
22. The engineered donor cell, nucleic acid construct, DNA molecule, plasmid, vector or composition as described in any one of claims 1 to 21, used in a method for treating a disease.
23. The method of claim 22, wherein the disease is selected from the group consisting of cancer, infectious diseases, autoimmune diseases, or hereditary diseases.
24. A miRNA hairpin, wherein the miRNA hairpin: (a) The target is a sequence selected from those having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with any of the sequences in SEQ ID NO: 1 to 128 or SEQ ID NO: 282 to 293; and / or (b) includes a sequence selected from any of the sequences in SEQ ID NO: 142 to 281 that has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity.
25. A VHH antibody or antibody fragment, wherein the VHH antibody or antibody fragment targets a polypeptide sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with any one of the sequences in SEQ ID NO: 1 to 129, SEQ ID NO: 130, SEQ ID NO: 131, SEQ ID NO: 132, SEQ ID NO: 133, or SEQ ID NO: 134; and / or wherein the VHH antibody or antibody fragment targets a polypeptide encoded by a polynucleotide sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with any one of the sequences in SEQ ID NO: 135, SEQ ID NO: 136, SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 139, or SEQ ID NO: 140.
Citation Information
Patent Citations
The frog prince, a transposon vector for gene transfer in vertebrates
EP1507865A2
Synthetic genes and genetic constructs comprising same i
US20020168707A1
Genetic inhibition by double-stranded RNA
US20030051263A1
Genetic inhibition by double-stranded RNA
US20030055020A1
Synthetic genes and genetic constructs comprising same I
US20030159161A1
